Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2018 Jul 19:349–386. doi: 10.1007/978-981-10-5311-5_20

Cysteine/Glutathione Deficiency: A Significant and Treatable Corollary of Disease

Pietro Ghezzi 3,#, Kevin V Lemley 4,#, James P Andrus 5,#, Stephen C De Rosa 6,#, Arne Holmgren 7, Dean Jones 8, Farook Jahoor 9, Richard Kopke 10, Ian Cotgreave 11, Teodoro Bottiglieri 12, Neil Kaplowitz 13, Hajime Nakamura 14, Frank Staal 15, Stephen W Ela 16, Kondala R Atkuri 17, Rabindra Tirouvanziam 18, Kartoosh Heydari 17, Bita Sahaf 4, Andrew Zolopa 20, Richard Eugene Frye 19, John J Mantovani 17, Leonard A Herzenberg 17, Leonore A Herzenberg 17,✉
Editors: Richard Eugene Frye1, Michael Berk2
PMCID: PMC7120747

Abstract

Glutathione (GSH) deficiency may play a pivotal role in a variety of apparently unrelated clinical conditions and diseases. Orally administered N-acetylcysteine (NAC), which replenishes the cysteine required for GSH synthesis, has been tested in a large number of randomized placebo-controlled trials involving these diseases and conditions. This chapter focused on developing a base of evidence suggesting that NAC administration improves disease by increasing cysteine and/or GSH in a variety of diseases, thereby implying a significant role for GSH deficiency in the clinical basis of many diseases. To develop this base of evidence, we systematically selected studies which considered the hypothesis that the therapeutic efficacy for NAC is an indication that cysteine and/or GSH deficiency is a pathophysiological part of the diseases studied. In this manner we focus this chapter on explaining the biological mechanisms of NAC therapy in a wide variety of disorders and demonstrate its ubiquitous role in improving disease that involves disrupted GSH and/or cysteine metabolism.

Electronic supplementary material

The online version of this article (10.1007/978-981-10-5311-5_20) contains supplementary material, which is available to authorized users.

Introduction

Life-threatening hepatotoxicity in the setting of acetaminophen (APAP) overdose is due to depletion of glutathione (GSH), a vital cysteine-containing tripeptide that protects cells and organs against oxidant injury. GSH depletion can occur when supplies of cysteine are inadequate to maintain GSH homeostasis in the face of the increased GSH consumption. Thus, rapid administration of N-acetylcysteine (NAC), which is converted to cysteine by first-pass metabolism and provides the cysteine necessary to replenish the depleted GSH, is the standard of care for preventing injury in APAP overdose.

GSH deficiency has also been recognized in a variety of apparently unrelated clinical conditions and diseases. NAC has been widely tested in randomized placebo-controlled trials (RPCTs) for efficacy in these diseases and conditions. In this chapter, we systematically review reports from early trials of NAC, which collectively suggest that GSH deficiency may be a common occurrence and that NAC may be a useful therapeutic adjunct for treating or preventing the development of this deficiency.

Methods

Publications included in this systematic literature review describe results from RPCT testing NAC for efficacy in a variety of disease settings. Publications were located by searching with the keywords “placebo AND N-acetylcysteine AND NOT animal” as well as “placebo AND N-acetylcysteine AND human, AND NOT animal.” We searched PubMed, the NLM database, the FDA website, Cochrane Database, Google, and subsequent material through 2006 and the references lists of all placebo- and non-placebo-controlled trials that we review here. This search identified nearly 2000 relevant publications. Within these, we identified 102 RPCTs that met the strict criteria for inclusion that we set for this review, i.e., publications reporting results from RPCT in which at least 10 subjects were used to test the efficacy of NAC administered without other drugs. Findings reported for these trials are summarized in tabular form (Online Tables 20.2 and 20.3) and discussed in the text. Trials excluded are listed in Online Table 20.1. Clinical studies relevant to the findings here but not conducted under strictly controlled conditions are found in Online Table 20.4.

Results

Glutathione (GSH)

Rapid administration of NAC is the standard of care for preventing hepatic injury in APAP overdose. The administered NAC is converted by first-pass metabolism to cysteine, which is needed to replenish the cysteine-containing intracellular tripeptide (l-γ-glutamyl-l-cysteinyl-glycine), commonly known as GSH. GSH is depleted during detoxification of excessive amounts of APAP. If it is not rapidly replenished, severe hepatic injury ensues.

In addition to this well-known use of NAC, at least 102 RPCTs conducted over 25 years have examined the effects of NAC treatment in respiratory, cardiovascular, endocrine, and infectious and other disease settings. Of these, 72 reported beneficial effects (Keays et al. 1991; Jackson et al. 1984; Ardissino et al. 1997; Andersen et al. 1995; Altomare et al. 1996; Aylward et al. 1980; Akerlund et al. 1996; Adair et al. 2001; Bromley et al. 1995; Badaloo et al. 2002; Boesgaard et al. 1992; Brocard et al. 1980; Bernard et al. 1997; Breitkreutz et al. 2000b; Bowles and Goral 1985; Diaz-Sandoval et al. 2002; Drager et al. 2004; De Mattia et al. 1998a, b; Dueholm et al. 1992; De Backer et al. 1996; De Flora et al. 1997; De Rosa et al. 2000; Estensen et al. 1999; Eren et al. 2003; Efrati et al. 2003; Evald et al. 1989; Fischer et al. 2004; Fulghesu et al. 2002; Ferrari 1980; Boman et al. 1983; Grassi 1980; Grassi and Morandini 1976; Horowitz et al. 1988a, b; Hansen et al. 1994; Heinig et al. 1985; Hauer et al. 2003; Herzenberg et al. 1997; Kay et al. 2003; Kasielski and Nowak 2001; McGavin 1985; MacNeill et al. 2003; Olivieri et al. 1985; Ovesen et al. 2000; Pace et al. 2003; Parr and Huitson 1987; Reinhart et al. 1995; Ratjen et al. 1985; Rasmussen and Glennow 1988; Rank et al. 2000; Shyu et al. 2002; Scholze et al. 2004; Spies et al. 1994, 1996; Spapen et al. 1998; Spada et al. 2002; Suter et al. 1994; Svendsen et al. 1989; Stafanger et al. 1988; Stafanger and Koch 1989; Tepel et al. 2000, 2003; Tepel and Zidek 2001; Tossios et al. 2003; Todisco et al. 1985; Verstraeten 1979; Van Schooten et al. 2002; Walters et al. 1986; Watt et al. 2002; Wiklund et al. 1996; Yalcin et al. 2002). Collectively, these findings suggest that cysteine/GSH deficiency contributes to the pathophysiology of a wide range of diseases and that treatment of this deficiency may be important in these diseases.

GSH is a central component of the oxidative-reductive (redox) apparatus of every cell. One of its key functions is to combine with, and thereby inactivate (detoxify), reactive oxygen species (ROS), other oxidative molecules, and certain drugs, exogenous chemicals, and toxins. Because GSH is depleted in these reactions, it must continually be replenished to maintain cell and organ viability and to support normal cellular functions. Drug intoxications resulting in severe GSH depletion, notably APAP overdose, cause extensive hepatic injury if treatment to replenish GSH is not initiated before GSH stores are depleted to below-critical protective levels.

Synthesis of GSH requires cysteine, a conditionally essential amino acid that must be obtained from dietary sources or by conversion of dietary methionine via the cystathionase pathway. If the supply of cysteine is adequate, normal GSH levels are maintained. In contrast, if supplies of cysteine are inadequate to maintain GSH homeostasis in the face of increased GSH consumption, GSH depletion occurs.

GSH depletion impacts a wide variety of cellular processes, ranging from DNA synthesis and gene expression to sugar metabolism and lactate production. The pleiotropic activity of this key intracellular molecule, which arose very early in evolution, derives from its participation in the energy economy and the synthetic and catabolic activities of virtually all cells. In higher animals, it also participates in regulating the expression or activity of extracellular molecules, including many of the cytokines and adhesion molecules implicated in inflammatory reactions and other disease processes.

Acute GSH depletion causes severe—often fatal—oxidative and/or alkylation injury. This injury can be prevented (e.g., in APAP overdose) by rapid treatment with NAC, an efficient nontoxic source of cysteine, which is able to replenish hepatocellular GSH. Chronic or slowly arising GSH deficiency due to administration of GSH-depleting drugs, or to diseases and conditions that deplete GSH, can be similarly debilitating (Taniguchi et al. 1989).

In this chapter, we first review evidence for a cysteine/GSH deficiency in a variety of disease settings and consider the biochemical mechanisms through which this deficiency, and its correction, can impact disease processes. We then consider findings from a large series of RPCT in which the effectiveness of NAC treatment has been investigated and discuss this in terms of cysteine/GSH replenishment.

GSH Deficiency and Disease

A role for GSH deficiency in the clinical manifestations of a broad spectrum of diseases and conditions is suggested either by the direct documentation of low GSH levels in these conditions or by the demonstration of significant improvement in patient condition following NAC administration. Over 70 RPCTs demonstrate beneficial effects of NAC treatment (Online Table 20.2) (Keays et al. 1991; Bromley et al. 1995; Estensen et al. 1999; Reinhart et al. 1995; Ardissino et al. 1997; Badaloo et al. 2002; Boesgaard et al. 1992; Horowitz et al. 1988a, b; Spies et al. 1996, 1994; Svendsen et al. 1989; Andersen et al. 1995; Eren et al. 2003; Fischer et al. 2004; Tossios et al. 2003; Altomare et al. 1996; Diaz-Sandoval et al. 2002; Drager et al. 2004; Efrati et al. 2003; Kay et al. 2003; MacNeill et al. 2003; Shyu et al. 2002; Tepel et al. 2000, 2003; Tepel and Zidek 2001; De Mattia et al. 1998a, b; Fulghesu et al. 2002; Pace et al. 2003; Ratjen et al. 1985; Stafanger et al. 1988; Stafanger and Koch 1989; Scholze et al. 2004; Wiklund et al. 1996; Aylward et al. 1980; Boman et al. 1983; Brocard et al. 1980; Dueholm et al. 1992; Evald et al. 1989; Ferrari 1980; Ferrari and Spinelli 1980; Grassi 1980; Grassi and Morandini 1976; Hansen et al. 1994; Heinig et al. 1985; Jackson et al. 1984; McGavin 1985; Parr and Huitson 1987; Rasmussen and Glennow 1988; Kasielski and Nowak 2001; Verstraeten 1979; Olivieri et al. 1985; Van Schooten et al. 2002; Todisco et al. 1985; Bernard et al. 1997; De Backer et al. 1996; Suter et al. 1994; Rank et al. 2000; Spapen et al. 1998; De Flora et al. 1997; Akerlund et al. 1996; Breitkreutz et al. 2000b; De Rosa et al. 2000; Herzenberg et al. 1997; Spada et al. 2002; Watt et al. 2002; Adair et al. 2001; Hauer et al. 2003; Ovesen et al. 2000; Walters et al. 1986; Yalcin et al. 2002; Bowles and Goral 1985) in diseases and conditions that include systemic inflammatory response syndrome (SIRS), acute respiratory distress syndrome (ARDS), chronic lung disease (CLD), chronic obstructive pulmonary disease (COPD), neurodegenerative disease, cardiovascular disease, alcoholism, infectious disease (e.g., HIV-1 infection and chronic hepatitis), hepatic and renal failure, diabetes, malnutrition, and certain autoimmune diseases.

The mechanisms that underlie the development of GSH deficiency in disease are reasonably well understood, at least in some instances. A wide variety of inflammatory and metabolic stimuli common during active disease increase the production of intracellular oxidants. In addition, neutrophils and other cells present at sites of inflammation release oxidants (reactive oxygen and nitrogen intermediates) that enter other cells and add to the internal oxidant burden. GSH provides the main defense against toxic oxidative intermediates by reducing and thereby inactivating them. However, in so doing, GSH is oxidized to GSH disulfide (GSSG). GSSG is then either rapidly reduced to GSH by GSSG reductase and NADPH or is excreted from the cell and only in part recovered from the circulation.

Factors that may contribute to GSH deficiency include GSH losses that occur when GSH is enzymatically conjugated to exogenous chemicals (drugs, dietary components, and toxins) and excreted from the cell as GSH or acetylcysteine mercapturates (conjugates). In addition, disease processes may decrease the cellular uptake or synthesis of cysteine or cystine, increase GSH efflux (Abrams et al. 1995), or increase the loss of cysteine/GSH sulfur due to accelerated oxidation to the final oxidized forms (sulfate and taurine) (Hortin et al. 1994; Breitkreutz et al. 2000a). Because a balance between cysteine supply and GSH utilization must be maintained, if oxidant production or levels of substrate for GSH conjugation are high and cysteine supplies for GSH replenishment become limiting, severe GSH deficiency may occur.

Importantly, there are significant potential iatrogenic contributions to GSH depletion. Inadvertent treatment with higher doses of APAP than patients can tolerate is perhaps the most common. This can be particularly dangerous for patients with conditions in which GSH depletion tends to occur as a consequence of the disease process or following treatment with drugs that are detoxified by GSH. In addition, long-term maintenance on parenteral nutrition may result in GSH depletion since parenteral nutrition formulations are not necessarily designed to provide adequate cysteine equivalents to meet the metabolic needs of diseased patients. In the absence of adequate attention to maintenance of adequate cysteine supplies, physicians and other caregivers can inadvertently contribute to GSH deficiency.

Patient behavior may also result in the development of GSH deficiency. Chronic over-consumption of alcohol is well known to deplete GSH in certain tissues, particularly the liver, and thus to render patients susceptible to APAP toxicity at doses well below those that cause toxicity in healthy individuals. Indeed, the FDA has issued a warning to this effect (www.fda.gov/ohrms/dockets/ac/02/briefing/3882b1.htm). However, chronic consumption of APAP or other GSH-depleting drugs, even well below toxic dose levels, can gradually deplete GSH to the point where these drugs elicit toxicity. Such practices become more dangerous if patients are malnourished or are GSH deficient for other reasons.

In summary, GSH deficiency occurs more frequently than previously suspected. GSH is readily replenished by de novo synthesis as long as sufficient supplies of cysteine are available, either directly from dietary sources or indirectly by conversion of dietary methionine. However, failure to obtain sufficient dietary cysteine to replace that lost when GSH is oxidized or conjugated to drugs or exogenous chemicals results in a deficiency in cysteine and/or GSH that may necessitate pharmacological intervention.

Dietary Sources of Cysteine

Cysteine utilized in the body is derived from dietary cysteine and methionine, sulfur-containing amino acids (SAAs) that are largely obtained from digested protein. Since mammals obtain cysteine both directly from the diet and by degradation of dietary methionine, the normal cysteine requirement can be satisfied from dietary sources. However, as indicated above, an additional source of cysteine may be required when cysteine loss (e.g., via GSH loss) outstrips the usual dietary supply.

Requirements for SAAs in humans are based upon nitrogen and SAA balance studies conducted with healthy individuals. The average American diet contains about 100 g of protein daily, greater than half of which is animal protein with a relatively high content of SAAs. The recommended daily allowance (RDA) for SAAs for an adult male is about 1 g (200 mg of methionine and an additional 810 mg of methionine that can be replaced by an equivalent amount of cysteine). A healthy, well-fed person will often consume greater than twice the SAA RDA. However, poor appetite and/or a tendency to select fresh food with low SAA content or bioavailability (Hitchins et al. 1989) or processed food depleted of SAAs (Volkin and Klibanov 1987; Schnackenberg et al. 2009; Briganti et al. 2008) can result in cysteine deficiency even in otherwise healthy people. Furthermore, as evidence here indicates, the need for SAAs can be substantially increased in many disease states.

The limited ability of the body to store amino acids is an additional problem. The human liver does contain a reservoir of cysteine (about 1 g) that is largely present in GSH. Since this amount approximates the daily SAA requirement, it provides only a short-term source to maintain a stable cysteine supply despite intermittent methionine and cysteine consumption. Under conditions of excessive cysteine requirements or deficient cysteine/methionine consumption, GSH is released from skeletal muscle and other tissues to supply cysteine. This results in decreased antioxidant and detoxification functions throughout the body. Consequently, even short-term inadequate intake of SAAs can pose a risk to individuals who may consume adequate amounts most of the time (Larsen and Fuller 1996; Shriner and Goetz 1992).

Mechanisms that May Mediate the Clinical Effects of Cysteine/GSH Deficiency

GSH has multiple roles in cells, ranging from neutralization of ROS to acting as a coenzyme in a variety of metabolic processes. The widespread participation of GSH in biochemical reactions of importance to cell growth, differentiation, and function offers mechanistic insights into how interfering with GSH homeostasis could influence the course of varied disease processes. A full discussion of the preclinical data bearing on these issues is beyond the scope of this review. However, to provide a mechanistic context for the clinical findings we discuss, we have summarized some of the key processes regulated by GSH in the following section.

Oxidative Reactions

In its best-known role, GSH participates in enzyme-mediated reactions to neutralize ROS, preventing the accumulation of ROS damage to DNA, proteins, and lipids. Glutathione peroxidases play a key role in this process by catalyzing the reaction of GSH with peroxides, including hydrogen peroxide and lipid peroxides. Thus, decreasing GSH can sharply augment oxidative damage and result in cell death or loss of function.

DNA Synthesis

Low GSH availability can impair DNA synthesis since GSH acts (via thioredoxin) as a coenzyme for ribonucleotide reductase, an enzyme required for the synthesis of DNA (Holmgren 1985, 1989; Zhong et al. 2000a).

Gene Expression and Signal Transduction

GSH has been shown to regulate or influence the expression of several genes, notably inflammatory genes under the control of transcription factor nuclear factor kappa B (NF-κB) and activator protein 1 (AP-1), even in settings where there is no marked overproduction of ROS. In addition, GSH has been shown to regulate T-cell signaling by controlling phosphorylation of phospholipase C γ 1 (PLCg1), which is required to stimulate the calcium flux that occurs early in the T-cell receptor-signaling cascade (Kanner et al. 1992a, b, c; Kanner and Ledbetter 1992; Flescher et al. 1994). Importantly, GSH has also been shown to regulate the expression of vascular cell adhesion molecule-1 (VCAM-1) on vascular endothelial cells, one of the early features in the pathogenesis of atherosclerosis and other inflammatory diseases (Ahmad et al. 2002; De Mattia et al. 1998a, b; Marui et al. 1993; Schmidt et al. 1995; Weigand et al. 2001).

Enzymes and Protein Functions

GSH regulates the activity of enzymes and other intracellular molecules by posttranslational modifications (glutathionylations) that control the oxidation state of protein-SH groups. When intracellular GSH is at its normal level for a particular cell type in a healthy individual, most of the free protein thiol groups are reduced, i.e., are present as protein-SH. In contrast, when GSH levels are low and/or GSSG levels are increased, GSH is reversibly coupled to many free thiols to create mixed disulfides (protein-S-S-G) (Ghezzi et al. 2002). These S-glutathionylated proteins, which may be functionally altered, then persist as such until GSH levels return to normal.

By controlling the activities of a series of enzymes and other intracellular proteins, glutathionylation can rapidly and reversibly alter the metabolic status of cells in response to changes in the redox environment. For example, glutathionylation has been shown to regulate actin polymerization (Wang et al. 2001), to inhibit the activity of several key enzymes (including glyceraldehyde-3-phosphate dehydrogenase, carbonic anhydrase, and protein tyrosine phosphatase), and to activate or stabilize other enzymes (including HIV-1 protease and the NF-ĸB transcription factor (Pineda-Molina et al. 2001)). Nitrosylation of protein thiols has similarly been shown to increase under oxidative conditions (Galli et al. 2002; Choudhary and Dudley 2002; Estevez and Jordan 2002; Yang et al. 2002) and to alter functions of key enzymes (Arnelle and Stamler 1995) and other molecules (Gow et al. 2002; Marshall et al. 2002). Thus, both glutathionylation and nitrosylation are of central importance to mechanisms through which cysteine/GSH deficiency may impact cell, and hence organ, function.

As indicated above, these types of posttranslational modifications are highly sensitive to shifts in the intracellular redox balance. They are rapidly initiated when GSH is depleted and rapidly reversed when GSH is replenished. As such, they provide the kind of flexible response to oxidative stress necessary for organisms living in an oxidative environment. However, at the extreme, they may underlie some of the pathologic changes that occur when chronic cysteine/GSH deficiency occurs in disease.

Glutaredoxin and Thioredoxin

Glutaredoxin (Grx) and thioredoxin (Trx) belong to the two major oxidoreductase enzyme families, which take electrons from GSH and NADPH respectively (Zhong et al. 2000a; Holmgren 1989; Cotgreave et al. 2002; Nakamura et al. 2001; Vlamis-Gardikas and Holmgren 2002). Trx and Grx interact with proteins to regulate functional activity, both directly and via glutathionylation. Intracellular GSH and GSSG levels play a major role in this regulation. The activity of Grx is directly regulated by the amount of intracellular GSH and GSSG, which controls the status of the Grx active site. The active sites in Trx (Cys-Gly-Pro-Cys) and Grx (Cys-Pro-Tyr-Cys) contain a dithiol that can be oxidized when GSH levels are low (or GSSG levels increase) to form an internal disulfide between the two cysteine residues or a mixed disulfide in which GSH is bound to one or both cysteine residues in the active site.

Formation of the Grx mixed disulfide (Casagrande et al. 2002; Cotgreave et al. 2002; Ghezzi et al. 2002) represents a special case of protein glutathionylation since it arms the Grx for glutathionylation of other proteins. Although Trx can also be glutathionylated (Casagrande et al. 2002), current data indicate that glutathionylation is mainly mediated by the Grx mixed disulfide (Daily et al. 2001; Shenton et al. 2002; Song et al. 2002). Oxidation of Grx and Trx active sites can also regulate Trx or Grx functions mediated by direct binding to key intracellular proteins. For example, under reducing conditions, Trx and Grx protect cells from apoptosis by binding to and inactivating apoptosis signaling kinase I (Song et al. 2002; Saitoh et al. 1998), whereas this binding is blocked, and apoptosis induction proceeds at low GSH levels (and/or high GSSG levels; Arner and Holmgren 2000).

Selenoenzymes

Decreasing GSH increases the intracellular redox potential of the GSH/GSSG redox couple and puts an additional burden on the Trx-Trx reductase system. This may be quite important in patients who have low selenium levels, since human Trx reductases are selenoenzymes with an essential selenocysteine residue in the active site (Arner and Holmgren 2000; Gladyshev et al. 1996a, b; Sandalova et al. 2001; Zhong et al. 2000a, b; Zhong and Holmgren 2000). Cysteine/GSH deficiency in these patients, in whom Trx reductase activity is compromised, may make them particularly susceptible to cell damage under oxidative stress. Thus, cysteine/GSH deficiency can impact cell and organ function through multiple pathways operating at the same or different sites, depending on the underlying mechanisms responsible for depleting GSH. The fact that multiple different pathways are affected explains why the effects of cysteine/GSH deficiency can affect many diseases and why cysteine/GSH deficiency has not been readily recognizable as a single clinical entity in the past.

N-Acetylcysteine (NAC) Treatment to Relieve Cysteine/GSH Deficiency

Clinical experience in the treatment of APAP toxicity has established that rapid administration of NAC, an essentially nontoxic cysteine source, restores normal GSH levels in solid tissues and the systemic circulation and thus prevents the potentially lethal consequences of severe cysteine/GSH deficiency induced by APAP overdose. In addition to this well-known role for NAC, NAC treatment has been shown to be clinically beneficial in a wide variety of diseases and conditions. In fact, over 70 RPCTs (Online Table 20.2) have reported beneficial effects of NAC treatment. Collectively, these studies demonstrate that cysteine/GSH deficiency is an important emerging clinical entity and that NAC administration offers an effective method for treating this deficiency.

Although various forms of cysteine and its precursors have been used as nutritional and therapeutic sources of cysteine, NAC is the most widely used and extensively studied. NAC is about ten times more stable than cysteine and much more soluble than the stable cysteine disulfide, cystine. l-2-oxothiazolidine-4-carboxylate (procysteine/OTC) has also been used effectively in some studies (Aaseth and Stoa-Birketvedt 2000) as have GSH and GSH monoethyl ester (Meister et al. 1986). In addition, dietary methionine is an effective source of cysteine, as is S-adenosylmethionine (referred to either as SAM or SAM-e) (Castagna et al. 1995). We focus on NAC in this review because NAC is the cysteine source used for correcting cysteine/GSH deficiency in most studies and because NAC is already approved for therapeutic use for treatment of APAP overdose and as a mucolytic agent in cystic fibrosis.

Surprisingly, given the diverse roles that GSH plays in cellular physiology and regulation of enzyme activity and protein function (see above), GSH deficiency has mainly been discussed from a clinical perspective in terms of the loss of intracellular protection against oxidative stress. Similarly, NAC is principally considered to be an antioxidant rather than a source of cysteine for GSH replenishment. However, while antioxidants such as vitamins E and C can spare GSH under conditions of oxidative stress, GSH loss due to oxidative or detoxifying reactions can only be offset by GSH resynthesis, which requires a cysteine source.

In addition to providing the cysteine necessary to replenish GSH, NAC administration improves the cysteine supply for protein synthesis and metabolic purposes. When administered intravenously, it also appears for a short period of time at high levels in blood and can react directly with oxidants and nitric oxide derivatives. However, when administered orally (as in most of the studies), it is rapidly converted by first-pass metabolism to cysteine, which is either incorporated into GSH in the liver or released into the blood in a regulated manner. Thus, orally administered NAC appears in the circulation only transiently and at only minimal levels. Hence, it is effective largely via its ability to increase cysteine supplies and thereby facilitate the GSH replenishment.

In the sections that follow, we discuss examples of RPCTs (Online Table 20.2) which have examined the outcomes of NAC therapy in various medical disorders. We also discuss selected findings from observational studies (Online Table 20.3) that further illuminate clinical aspects of cysteine/GSH deficiency.

Acetaminophen Toxicity

APAP overdose is a well-known cause of fulminant hepatic failure. In fact, APAP overdose and idiosyncratic drug reactions have now replaced viral hepatitis as the most frequent causes of acute liver failure in the United States (Ostapowicz and Lee 2000). The toxicity of APAP is due to depletion of GSH in hepatocytes (Mitchell et al. 1974, 1981; Peterson and Rumack 1978; Lauterburg et al. 1983; Smilkstein et al. 1988; Ostapowicz et al. 2002). NAC is extremely effective in preventing liver damage due to APAP toxicity. NAC administered promptly and at a sufficient dose is the standard of care for treatment of APAP poisoning (Mitchell et al. 1974; Lyons et al. 1977; Prescott et al. 1977; Peterson and Rumack 1977a, b, 1978; Marquardt 1977; Maurer and Zeisler 1978; Macy 1979; Stewart et al. 1979; Bailey 1980; Black 1980; Sellers and Freedman 1981; Rumack et al. 1981; Prescott and Critchley 1983; Miller and Rumack 1983; Rumack 1984, 1986, 2002; Davis 1986; Larrauri et al. 1987; Slattery et al. 1987, 1989; Smilkstein et al. 1988, 1991; Burgunder et al. 1989; Beckett et al. 1990, 1985; Harrison et al. 1990; Keays et al. 1991; Bray et al. 1991; Winkler and Halkin 1992; Lee 1993, 1995, 1996; Larsen and Fuller 1996; De Roos and Hoffman 1996; Perry and Shannon 1998; Salgia and Kosnik 1999; Ammenti et al. 1999; Buckley et al. 1999; Broughan and Soloway 2000; Kearns et al. 2000; Woo et al. 2000; Amirzadeh and McCotter 2002; Schmidt et al. 2002; Jones 2002; Kearns 2002; Peterson et al. 1998) and can improve survival (Harrison et al. 1990) and cardiovascular function (Harrison et al. 1991) in those already with hepatic failure.

Interestingly, although the acute dose of APAP likely to cause severe liver toxicity is well established for healthy individuals (Peterson and Rumack 1978), under conditions in which GSH levels are compromised, doses of APAP that are within the usual prescribed range can cause hepatic injury (Peterson and Rumack 1978; Larsen and Fuller 1996). Thus, usage of APAP and other GSH-depleting drugs may be quite important to overall pathology in diseases and conditions where GSH deficiency is known to occur.

This is especially important in patients with chronic alcohol consumption (Bray et al. 1991; Salgia and Kosnik 1999) because they often have lower GSH levels. In such patients, doses of APAP below those usually considered toxic could deplete GSH below the critical threshold for hepatocellular necrosis (Lauterburg and Velez 1988). Thus, it has been suggested that patients with chronic alcoholism and suspected APAP poisoning should be treated with NAC regardless of risk estimation (Johnston and Pelletier 1997; Ozaras et al. 2003; Moss et al. 2000). This has prompted the FDA to a special warning for individuals with chronic alcohol use in regard to APAP use.

Gastrointestinal Disease

Several studies have demonstrated GSH depletion in children with the edematous syndromes of protein-energy malnutrition (PEM), kwashiorkor, and marasmic kwashiorkor (Badaloo et al. 2002; Golden and Ramdath 1987; Jackson 1986; Reid et al. 2000). Children with edematous PEM have biomarkers of oxidant damage (Lenhartz et al. 1998; Fechner et al. 2001). The observation that biomarkers of oxidant damage normalize as soon as clinical signs and symptoms resolve (Lenhartz et al. 1998) suggests that oxidant damage plays an important role in the pathogenesis of the disease.

In a study of children with edematous PEM, Jahoor and colleagues showed that RBC GSH depletion is due to a slower rate of GSH synthesis secondary to inadequate cysteine availability (Reid et al. 2000). In another study of children with edematous PEM, Jahoor and colleagues demonstrated that GSH synthesis rate and concentration can be restored during the early phase of nutritional rehabilitation if diets are supplemented with NAC (Badaloo et al. 2002). The observation that edema is lost at a faster rate by the group whose GSH pools were restored early with NAC suggests that early restoration of GSH homeostasis accelerates recovery. This possibility is supported by another study showing that increases in GSH levels in children with kwashiorkor are associated with recovery (Fechner et al. 2001).

These findings also raise the question of whether the modest malnutrition common in elderly people, who also frequently have low GSH levels (Anderson et al. 1993, 2001), puts the elderly at risk for developing clinically significant cysteine/GSH deficiency and hence at increased risk of hepatic and other tissue injuries associated with consumption of GSH-depleting pharmaceuticals such as APAP.

Kidney Transplantation

Delayed graft function (DGF) after kidney transplantation is probably in large part caused by production of ROS following reperfusion of the transplant organ after a period of warm and cold ischemia. In general, these reactive molecules are detoxified by GSH-dependent mechanisms, including conjugation to GSH by a family of GSH-S-transferase (GST) enzymes, some of which are expressed in large quantity in the proximal tubule of the kidney (Davies et al. 1995). In an observational study of 229 kidney transplant recipients, donor (but not recipient) GST M1B polymorphism was associated with significantly lower rates of DGF after transplantation (Akgul et al. 2012).

Diabetes Mellitus

Three RPCTs demonstrate beneficial effects of NAC treatment in insulin-related disease (Online Table 20.2d). One study demonstrates that oral administration of NAC to patients with non-insulin-dependent diabetes mellitus reverses the elevation of soluble vascular cell adhesion molecule-1 (De Mattia et al. 1998b), a substance that promotes accumulation of macrophages and T lymphocytes at sites of inflammation and increases progression of vascular damage (Marui et al. 1993; Schmidt et al. 1995). A second placebo-controlled study by the same group shows that intravenous GSH infusion significantly increases both RBC GSH/GSSG redox ratio and total glucose uptake in these patients and suggests that abnormal intracellular GSH redox status plays an important role in reducing insulin sensitivity (De Mattia et al. 1998a). Consistent with these findings, in an ongoing study in type 2 diabetics, Jahoor and colleagues have demonstrated that 2 weeks of dietary supplementation with NAC elicited significant increases in both RBC GSH concentration and synthesis, suggesting that positive clinical effects of NAC are mediated through improved GSH availability (McKay et al. 2000).

Metabolic and Genetic Disease

Genetic defects that impair GSH synthesis or homeostasis are well known (Ristoff and Larsson 2002). The most common defect affects GSH synthetase (GS) and has a wide range of disease manifestations, including hemolytic anemia, progressive neurological symptoms, metabolic acidosis, and, in the most severe form, death during the neonatal period. Data from a small observational study suggests that early supplementation with Vitamins C and E may improve long-term outcome in these patients (Ristoff et al. 2001).

Systemic Inflammatory Response Syndrome

Five of seven RPCTs showed a beneficial effect of NAC as an adjunct therapy for acute lung injury and end-organ failure. These studies indicate that oxidative stress and cysteine/GSH depletion play a major role in inflammation leading to capillary leak syndromes and end-organ failure (De Flora et al. 1997; Suter et al. 1994; Rank et al. 2000). These study show that NAC: (a) decreases the cytotoxic effects of TNF-α and other inflammatory cytokines (Zimmerman et al. 1989), (b) decreases neutrophil elastase production in acute lung injury (Borregaard et al. 1987; De Backer et al. 1996; Laurent et al. 1996; Eklund et al. 1988; Moriuchi et al. 1998), and (c) increases neutrophil protection and decreases mortality in septic shock (Villa et al. 2002).

HIV Disease

A broad series of studies clearly demonstrates GSH levels in RBCs, lymphocytes, and other peripheral blood mononuclear cells progressively decrease as HIV disease advances (De Rosa et al. 2000; Herzenberg et al. 1997; Akerlund et al. 1996; Droge and Breitkreutz 1999; Clotet et al. 1995; Spada et al. 2002; Verhagen et al. 2001). In addition, careful pharmacokinetic studies demonstrate that the low GSH in HIV-infected individuals is due to limited availability of sufficient cysteine to maintain cellular GSH homeostasis (Droge et al. 1991; Roederer et al. 1990). In fact, a massive peripheral tissue catabolism of sulfur-containing peptides and amino acids has been observed in HIV patients (Hortin et al. 1994; Breitkreutz et al. 2000a).

Five of six RPCTs show beneficial effects of NAC treatment in HIV infection. Several trials collectively demonstrated that NAC administration to HIV-infected subjects with low GSH levels replenishes lymphocyte and erythrocyte GSH (Online Table 20.2g) (De Rosa et al. 2000; Breitkreutz et al. 2000b). Importantly, one of these studies demonstrates that NAC treatment significantly improves T-cell function (Breitkreutz et al. 2000b). This finding supports the idea that cysteine/GSH deficiency contributes to the immunodeficiency in HIV-infected individuals and plays an important and reversible role in the functional impairment of those T cells that are still present at later stages of HIV disease.

Cysteine/GSH deficiency may also contribute to the failure of the innate immune system and the development of opportunistic infections in the final stages of HIV disease. Observational studies have shown that HIV-infected individuals with low CD4 T-cell counts and low cellular and systemic GSH levels frequently have elevated blood levels of Trx, which is an effective chemokine (Bertini et al. 1999). In mice, circulating Trx (like other chemokines) blocks neutrophil migration to infection sites and hence interferes with innate defense against invading pathogens (Villa et al. 2002). Similar interference may occur in HIV infection, since the survival of infected individuals with Trx levels above the normal range is significantly decreased compared to survival of subjects with Trx levels in the normal range (Ghezzi et al. 2002). Since NAC treatment lowers Trx levels (Nakamura et al. 2001, 2002), this may contribute to the observed association between NAC ingestion and prolonged survival in HIV disease (Roederer et al. 1992; De Rosa et al. 2000; Akerlund et al. 1996; Spada et al. 2002).

The improvement in T-cell function observed in HIV-infected subjects treated with NAC (Breitkreutz et al. 2000b) suggests that NAC treatment may be a useful adjunct in HIV vaccination. In addition, this improvement provides a rationale for the strong associations observed between low GSH levels and decreased survival in HIV infection (Herzenberg et al. 1997) and between NAC administration and improved survival in an open-label NAC study (Huengsberg et al. 1998).

Otic Disease

Preclinical studies point to the importance of oxidative stress and GSH depletion in the genesis of noise and toxin-induced hearing loss (Kopke et al. 1999, 2001). Medications with inner ear toxicity such as aminoglycoside antibiotics and the chemotherapy agent cisplatin damage the cochlea through the generation of oxygen free radicals. Hearing loss and cochlear damage associated with administration of these compounds have been shown, in animal models, to be greatly reduced by administration of both NAC and methionine (Hoffer et al. 2001; Kopke et al. 2000; Sha and Schacht 2000). Similarly, studies with animal models show that permanent cochlear damage due to acute acoustic overexposure, which induces ischemia reperfusion, glutamate excitotoxicity, free radical generation, and GSH depletion (Kopke et al. 1999, 2000, 2001, 2002), can be almost completely prevented by systemic administration of NAC or methionine (Kopke et al. 2000, 2002).

Summary

The evidence reviewed here reveals cysteine/GSH deficiency as an emerging clinical entity. The manifestations of this deficiency may vary in different disease settings, as may the biochemical mechanisms that mediate its effects. However, they are united by a common positive response to NAC therapy in RPCTs (Online Table 20.2). The studies we have reviewed collectively argue for consideration of cysteine/GSH deficiency as a significant and treatable clinical entity.

Surprisingly, given the diverse roles that GSH plays in cellular physiology and regulation of enzyme activity and protein function, the consequences of low GSH levels have mainly been discussed from a clinical perspective in terms of the loss of protection against intracellular oxidative stress. However, while antioxidants such as vitamins E and C can spare GSH under conditions of oxidative stress, GSH loss can only be offset by GSH resynthesis, indicating a central role for this molecule over and above its ability to counteract the effects of intracellular oxidants.

Similarly, although NAC is a well-known source of cysteine for GSH replenishment in APAP toxicity, it is principally cast as an antioxidant in other settings. By and large, physicians and the lay public tend to equate NAC with vitamins C and E and other antioxidants. Like GSH, NAC can serve as an antioxidant. However, while other antioxidants can replace NAC and GSH in this role, only NAC or another cysteine source can provide the raw material necessary to replenish GSH and enable GSH-dependent biochemical reactions.

We have pointed out that physicians may find NAC administration useful as adjunct therapy for diseases and conditions in which cysteine/GSH deficiency is likely to play a role. The positive findings in the RPCTs we have discussed support this argument. However, the absence of large multicenter trials testing NAC in various settings leaves this as an open question. The recognition that cysteine/GSH deficiency is an important clinical entity will encourage support for such trials.

In the meantime, the findings we have discussed suggests that patients with diseases or conditions in which cysteine/GSH deficiency has been demonstrated may be well advised to avoid unnecessary exposures to medications that may exacerbate GSH depletion. In fact, when advising such patients, it seems reasonable for physicians to emphasize that alcohol usage be kept at modest levels and that APAP usage should be kept strictly within the recommended dosing.

The availability of OTC NAC, and the low toxicity of this cysteine prodrug in situations where it has been tested, opens the possibility of patient- or physician-initiated therapy. However, if such therapy is elected, we suggest that the NAC preparation(s) used be prepared under Good Manufacturing Practice conditions and packaged to prevent oxidation of the product.

Electronic Supplementary Material

Online Table 20.1 (15.7KB, docx)

Studies excluded from this review (DOCX 31 kb)

Online Table 20.2 (40.5KB, docx)

NAC treatment in randomized placebo-controlled studies (DOCX 60 kb)

Online Table 20.3 (27.4KB, docx)

Intravenous (IV) NAC (DOCX 44 kb)

Online Table 20.4 (42.6KB, docx)

Observational NAC treatment studies (DOCX 40 kb)

Acknowledgments

This presentation would not have been completed without the help from Mr. David Aiello (BioAdvantex Pharma, Mississauga, Ontario, Canada) and Dr. Thilo Messerschmidt (Diamalt B.F. Goodrich, Raubling, Germany). Mr. Aiello helped ferret out and interpret citations of importance for this manuscript and provided key editorial and technical support when we needed it most. Dr. Messerschmidt provided highly valuable technical and biochemical insights in addition to editorial advice concerning NAC synthesis and the mechanisms involved in maintaining the redox balance in cells and organisms. Mr. Onny Chattergee and Mr. Kevin McCaffrey provided unstinting technical help in the organization and handling of the many publications reviewed here, and Ms. Claudia Weber provided the solid administrative support that allowed us to focus on the mammoth job of collecting and reviewing all of these publications. Studies presented here were supported in part by a grant (CA-42509) from the National Cancer Institute of the US National Institutes of Health.

Contributor Information

Richard Eugene Frye, Phone: +11281-546-8377, FAX: +11501-978-6483, Email: REFrye@uams.edu.

Michael Berk, Phone: +61613 4215 3320, FAX: +61613 4215 3491, Email: mikebe@barwonhealth.org.au.

Leonore A. Herzenberg, Email: leeherz@stanford.edu

References

  1. Aaseth J, Stoa-Birketvedt G. Glutathione in overweight patients with poorly controlled type 2 diabetes. J Trace Elem Exp Med. 2000;13(1):105–111. doi: 10.1002/(SICI)1520-670X(2000)13:1<105::AID-JTRA12>3.0.CO;2-B. [DOI] [Google Scholar]
  2. Abrams D, Cotton D, Mayer K. AIDS/HIV treatment directory, vol 7 #4. Rockville, MD: American Foundation for AIDS Research (AmFAR); 1995. [Google Scholar]
  3. Adair JC, Knoefel JE, Morgan N. Controlled trial of N-acetylcysteine for patients with probable Alzheimer’s disease. Neurology. 2001;57(8):1515–1517. doi: 10.1212/WNL.57.8.1515. [DOI] [PubMed] [Google Scholar]
  4. Agusti AG, Togores B, Ibanez J, Raurich JM, Maimo A, Bergada J, Marse P, Jorda R. Effects of N-acetylcysteine on tissue oxygenation in patients with multiple organ failure and evidence of tissue hypoxia. Eur Respir J. 1997;10(9):1962–1966. doi: 10.1183/09031936.97.10091962. [DOI] [PubMed] [Google Scholar]
  5. Ahmad M, Zhang Y, Papharalambus C, Alexander RW. Role of isoprenylcysteine carboxyl methyltransferase in tumor necrosis factor-alpha stimulation of expression of vascular cell adhesion molecule-1 in endothelial cells. Arterioscler Thromb Vasc Biol. 2002;22(5):759–764. doi: 10.1161/01.ATV.0000015884.61894.DC. [DOI] [PubMed] [Google Scholar]
  6. Ahola T, Lapatto R, Raivio KO, Selander B, Stigson L, Jonsson B, Jonsbo F, Esberg G, Stovring S, Kjartansson S, Stiris T, Lossius K, Virkola K, Fellman V. N-acetylcysteine does not prevent bronchopulmonary dysplasia in immature infants: a randomized controlled trial. J Pediatr. 2003;143(6):713–719. doi: 10.1067/S0022-3476(03)00419-0. [DOI] [PubMed] [Google Scholar]
  7. Akerlund B, Jarstrand C, Lindeke B, Sonnerborg A, Akerblad A-C, Rasool O. Effect of N-acetylcysteine (NAC) treatment on HIV-1 infection: a double-blind placebo-controlled trial. Eur J Clin Pharmacol. 1996;50(6):457–461. doi: 10.1007/s002280050140. [DOI] [PubMed] [Google Scholar]
  8. Akerlund B, Tynell E, Bratt G, Bielenstein M, Lidman C. N-acetylcysteine treatment and the risk of toxic reactions to trimethoprim-sulphamethoxazole in primary Pneumocystis carinii prophylaxis in HIV-infected patients. J Infect. 1997;35(2):143–147. doi: 10.1016/S0163-4453(97)91578-4. [DOI] [PubMed] [Google Scholar]
  9. Akgul SU, Oguz FS, Caliskan Y, Kekik C, Gurkan H, Turkmen A, Nane I, Aydin F. The effect of glutathione S-transferase polymorphisms and anti-GSTT1 antibodies on allograft functions in recipients of renal transplant. Transplant Proc. 2012;44(6):1679–1684. doi: 10.1016/j.transproceed.2012.04.004. [DOI] [PubMed] [Google Scholar]
  10. Allaqaband S, Tumuluri R, Malik AM, Gupta A, Volkert P, Shalev Y, Bajwa TK. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv. 2002;57(3):279–283. doi: 10.1002/ccd.10323. [DOI] [PubMed] [Google Scholar]
  11. Allard JP, Aghdassi E, Chau J, Tam C, Kovacs CM, Salit IE, Walmsley SL. Effects of vitamin E and C supplementation on oxidative stress and viral load in HIV-infected subjects. AIDS. 1998;12(13):1653–1659. doi: 10.1097/00002030-199813000-00013. [DOI] [PubMed] [Google Scholar]
  12. Altomare E, Colonna P, Dagostino C, Castellaneta G, Vendemiale G, Grattagliano I, Cirelli F, Bovenzi F, Colonna L. High-dose antioxidant therapy during thrombolysis in patients with acute myocardial infarction. Curr Ther Res. 1996;57(2):131–141. doi: 10.1016/S0011-393X(96)80007-5. [DOI] [Google Scholar]
  13. Altomare E, Vendemiale G, Albano O. Hepatic glutathione content in patients with alcoholic and non alcoholic liver disease. Life Sci. 1988;43:991–998. doi: 10.1016/0024-3205(88)90544-9. [DOI] [PubMed] [Google Scholar]
  14. Amirzadeh A, McCotter C. The intravenous use of oral acetylcysteine (mucomyst) for the treatment of acetaminophen overdose. Arch Intern Med. 2002;162(1):96–97. doi: 10.1001/archinte.162.1.96. [DOI] [PubMed] [Google Scholar]
  15. Ammenti A, Ferrante R, Spagna A. Renal impairment without hepatic damage after acetaminophen overdose. Pediatr Nephrol. 1999;13(3):271–272. [PubMed] [Google Scholar]
  16. Andersen LW, Thiis J, Kharazmi A, Rygg I. The role of N-acetylcystein administration on the oxidative response of neutrophils during cardiopulmonary bypass. Perfusion. 1995;10(1):21–26. doi: 10.1177/026765919501000105. [DOI] [PubMed] [Google Scholar]
  17. Anderson BB, Giuberti M, Perry GM, Salsini G, Casadio I, Vullo C. Low red blood cell glutathione reductase and pyridoxine phosphate oxidase activities not related to dietary riboflavin: selection by malaria? Am J Clin Nutr. 1993;57(5):666–672. doi: 10.1093/ajcn/57.5.666. [DOI] [PubMed] [Google Scholar]
  18. Anderson RA, Roussel AM, Zouari N, Mahjoub S, Matheau JM, Kerkeni A. Potential antioxidant effects of zinc and chromium supplementation in people with type 2 diabetes mellitus. J Am Coll Nutr. 2001;20(3):212–218. doi: 10.1080/07315724.2001.10719034. [DOI] [PubMed] [Google Scholar]
  19. Andrews NP, Prasad A, Quyyumi AA. N-acetylcysteine improves coronary and peripheral vascular function. J Am Coll Cardiol. 2001;37(1):117–123. doi: 10.1016/S0735-1097(00)01093-7. [DOI] [PubMed] [Google Scholar]
  20. Angulo P, Lindor KD. Treatment of nonalcoholic fatty liver: present and emerging therapies. Semin Liver Dis. 2001;21(1):81–88. doi: 10.1055/s-2001-12931. [DOI] [PubMed] [Google Scholar]
  21. App EM, Baran D, Dab I, Malfroot A, Coffiner M, Vanderbist F, King M. Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis. Eur Respir J. 2002;19(2):294–302. doi: 10.1183/09031936.02.00025802. [DOI] [PubMed] [Google Scholar]
  22. Ardissino D, Merlini PA, Savonitto S, Demicheli G, Zanini P, Bertocchi F, Falcone C, Ghio S, Marinoni G, Montemartini C, Mussini A. Effect of transdermal nitroglycerin or N-acetylcysteine, or both, in the long-term treatment of unstable angina pectoris. J Am Coll Cardiol. 1997;29(5):941–947. doi: 10.1016/S0735-1097(97)00005-3. [DOI] [PubMed] [Google Scholar]
  23. Arnelle DR, Stamler JS. NO+, NO, and NO- donation by S-nitrosothiols: implications for regulation of physiological functions by S-nitrosylation and acceleration of disulfide formation. Arch Biochem Biophys. 1995;318(2):279–285. doi: 10.1006/abbi.1995.1231. [DOI] [PubMed] [Google Scholar]
  24. Arner ES, Holmgren A. Physiological functions of thioredoxin and thioredoxin reductase. Eur J Biochem. 2000;267(20):6102–6109. doi: 10.1046/j.1432-1327.2000.01701.x. [DOI] [PubMed] [Google Scholar]
  25. Aukrust P, Svardal AM, Muller F, Lunden B, Berge RK, Froland SS. Decreased levels of total and reduced glutathione in CD4+ lymphocytes in common variable immunodeficiency are associated with activation of the tumor necrosis factor system: possible immunopathogenic role of oxidative stress. Blood. 1995;86(4):1383–1391. [PubMed] [Google Scholar]
  26. Aylward M, Maddock J, Dewland P. Clinical evaluation of acetylcysteine in the treatment of patients with chronic obstructive bronchitis: a balanced double-blind trial with placebo control. Eur J Respir Dis Suppl. 1980;111:81–89. [PubMed] [Google Scholar]
  27. Badaloo A, Reid M, Forrester T, Heird WC, Jahoor F. Cysteine supplementation improves the erythrocyte glutathione synthesis rate in children with severe edematous malnutrition. Am J Clin Nutr. 2002;76(3):646–652. doi: 10.1093/ajcn/76.3.646. [DOI] [PubMed] [Google Scholar]
  28. Bailey BO. Acetaminophen hepatotoxicity and overdose. Am Fam Physician. 1980;22(1):83–87. [PubMed] [Google Scholar]
  29. Bains JS, Shaw CA. Neurodegenerative disorders in humans: the role of glutathione in oxidative stress-mediated neuronal death. Brain Res Rev. 1997;25(3):335–358. doi: 10.1016/S0165-0173(97)00045-3. [DOI] [PubMed] [Google Scholar]
  30. Banaclocha MM. Therapeutic potential of N-acetylcysteine in age-related mitochondrial neurodegenerative diseases. Med Hypotheses. 2001;56(4):472–477. doi: 10.1054/mehy.2000.1194. [DOI] [PubMed] [Google Scholar]
  31. Banerjee BD, Seth V, Bhattacharya A, Pasha ST, Chakraborty AK. Biochemical effects of some pesticides on lipid peroxidation and free-radical scavengers. Toxicol Lett. 1999;107(1–3):33–47. doi: 10.1016/S0378-4274(99)00029-6. [DOI] [PubMed] [Google Scholar]
  32. Barbaro G, Di Lorenzo G, Soldini M, Bellomo G, Belloni G, Grisorio B, Barbarini G. Vagal system impairment in human immunodeficiency virus-positive patients with chronic hepatitis C: does hepatic glutathione deficiency have a pathogenetic role? Scand J Gastroenterol. 1997;32(12):1261–1266. doi: 10.3109/00365529709028157. [DOI] [PubMed] [Google Scholar]
  33. Barbaro G, Di Lorenzo G, Soldini M, Parrotto S, Bellomo G, Belloni G, Grisorio B, Barbarini G. Hepatic glutathione deficiency in chronic hepatitis C: quantitative evaluation in patients who are HIV positive and HIV negative and correlations with plasmatic and lymphocytic concentrations and with the activity of the liver disease. Am J Gastroenterol. 1996;91(12):2569–2573. [PubMed] [Google Scholar]
  34. Barditch-Crovo P, Noe D, Skowron G, Lederman M, Kalayjian RC, Borum P, Buier R, Rowe WB, Goldberg D, Lietman P. A phase I/II evaluation of oral L-2-oxothiazolidine-4-carboxylic acid in asymptomatic patients infected with human immunodeficiency virus. J Clin Pharmacol. 1998;38(4):357–363. doi: 10.1002/j.1552-4604.1998.tb04435.x. [DOI] [PubMed] [Google Scholar]
  35. Barton AD. Aerosolized detergents and mucolytic agents in the treatment of stable chronic obstructive pulmonary disease. Am Rev Respir Dis. 1974;110(6 Pt 2):104–110. doi: 10.1164/arrd.1974.110.6P2.104. [DOI] [PubMed] [Google Scholar]
  36. Beckett GJ, Chapman BJ, Dyson EH, Hayes JD. Plasma glutathione S-transferase measurements after paracetamol overdose: evidence for early hepatocellular damage. Gut. 1985;26(1):26–31. doi: 10.1136/gut.26.1.26. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Beckett GJ, Donovan JW, Hussey AJ, Proudfoot AT, Prescott LF. Intravenous N-acetylcysteine, hepatotoxicity and plasma glutathione S-transferase in patients with paracetamol overdosage. Hum Exp Toxicol. 1990;9(3):183–186. doi: 10.1177/096032719000900311. [DOI] [PubMed] [Google Scholar]
  38. Behr J, Degenkolb B, Krombach F, Vogelmeier C. Intracellular glutathione and bronchoalveolar cells in fibrosing alveolitis: effects of N-acetylcysteine. Eur Respir J. 2002;19(5):906–911. doi: 10.1183/09031936.02.00204902. [DOI] [PubMed] [Google Scholar]
  39. Behr J, Maier K, Degenkolb B, Krombach F, Vogelmeier C. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Adjunctive therapy to maintenance immunosuppression. Am J Respir Crit Care Med. 1997;156(6):1897–1901. doi: 10.1164/ajrccm.156.6.9706065. [DOI] [PubMed] [Google Scholar]
  40. Beloqui O, Prieto J, Suarez M, Gil B, Qian CH, Garcia N, Civeira MP. N-acetyl cysteine enhances the response to interferon-alpha in chronic hepatitis-C: a pilot study. J Interf Res. 1993;13:279–282. doi: 10.1089/jir.1993.13.279. [DOI] [PubMed] [Google Scholar]
  41. Ben-Ari Z, Vaknin H, Tur-Kaspa R. N-acetylcysteine in acute hepatic failure (Non-paracetamol-induced) Hepatogastroenterology. 2000;47(33):786–789. [PubMed] [Google Scholar]
  42. Ben-Menachem E, Kyllerman M, Marklund S. Superoxide dismutase and glutathione peroxidase function in progressive myoclonus epilepsies. Epilepsy Res. 2000;40(1):33–39. doi: 10.1016/S0920-1211(00)00096-6. [DOI] [PubMed] [Google Scholar]
  43. Bernard GR. Potential of N-acetylcysteine as treatment for the adult respiratory distress syndrome. Eur Respir J Suppl. 1990;11:496s–498s. [PubMed] [Google Scholar]
  44. Bernard GR, Wheeler AP, Arons MM, Morris PE, Paz HL, Russell JA, Wright PE, Bernard GR, Arons MM, Wheeler AP, Carmichael LC, Morris PE, Higgins SB, Dupont WD, Edens TR, Swindell BB, Russell JA, Paz HL, Wright PE, Steinberg KP. A trial of antioxidants N-acetylcysteine and procysteine in ARDS. Chest. 1997;112(1):164–172. doi: 10.1378/chest.112.1.164. [DOI] [PubMed] [Google Scholar]
  45. Bernhard MC, Junker E, Hettinger A, Lauterburg BH. Time course of total cysteine, glutathione and homocysteine in plasma of patients with chronic hepatitis C treated with interferon-alpha with and without supplementation with N-acetylcysteine. J Hepatol. 1998;28(5):751–755. doi: 10.1016/S0168-8278(98)80223-7. [DOI] [PubMed] [Google Scholar]
  46. Bertini R, Howard OM, Dong HF, Oppenheim JJ, Bizzarri C, Sergi R, Caselli G, Pagliei S, Romines B, Wilshire JA, Mengozzi M, Nakamura H, Yodoi J, Pekkari K, Gurunath R, Holmgren A, Herzenberg LA, Ghezzi P. Thioredoxin, a redox enzyme released in infection and inflammation, is a unique chemoattractant for neutrophils, monocytes, and T cells. J Exp Med. 1999;189(11):1783–1789. doi: 10.1084/jem.189.11.1783. [DOI] [PMC free article] [PubMed] [Google Scholar]
  47. Bianchi G, Bugianesi E, Ronchi M, Fabbri A, Zoli M, Marchesini G. Glutathione kinetics in normal man and in patients with liver cirrhosis. J Hepatol. 1997;26(3):606–613. doi: 10.1016/S0168-8278(97)80426-6. [DOI] [PubMed] [Google Scholar]
  48. Bibi H, Seifert B, Oullette M, Belik J. Intratracheal N-acetylcysteine use in infants with chronic lung disease. Acta Paediatr. 1992;81(4):335–339. doi: 10.1111/j.1651-2227.1992.tb12238.x. [DOI] [PubMed] [Google Scholar]
  49. Bijlmer-Iest JC, Baart de la Faille H, van Asbeck BS, van Hattum J, van Weelden H, Marx JJ, Koningsberger JC. Protoporphyrin photosensitivity cannot be attenuated by oral N-acetylcysteine. Photodermatol Photoimmunol Photomed. 1992;9(6):245–249. [PubMed] [Google Scholar]
  50. Black M. Acetaminophen hepatotoxicity. Gastroenterology. 1980;78(2):382–392. [PubMed] [Google Scholar]
  51. Boccalandro F, Amhad M, Smalling RW, Sdringola S. Oral acetylcysteine does not protect renal function from moderate to high doses of intravenous radiographic contrast. Catheter Cardiovasc Interv. 2003;58(3):336–341. doi: 10.1002/ccd.10389. [DOI] [PubMed] [Google Scholar]
  52. Boesgaard S, Aldershvile J, Pedersen F, Pietersen A, Madsen JK, Grande P. Continuous oral N-acetylcysteine treatment and development of nitrate tolerance in patients with stable angina pectoris. J Cardiovasc Pharmacol. 1991;17(6):889–893. doi: 10.1097/00005344-199106000-00005. [DOI] [PubMed] [Google Scholar]
  53. Boesgaard S, Aldershvile J, Poulsen HE. Preventive administration of intravenous N-acetylcysteine and development of tolerance to isosorbide dinitrate in patients with angina pectoris. Circulation. 1992;85(1):143–149. doi: 10.1161/01.CIR.85.1.143. [DOI] [PubMed] [Google Scholar]
  54. Boman G, Backer U, Larsson S, Melander B, Wahlander L. Oral acetylcysteine reduces exacerbation rate in chronic bronchitis: report of a trial organized by the Swedish Society for Pulmonary Diseases. Eur J Respir Dis. 1983;64(6):405–415. [PubMed] [Google Scholar]
  55. Bondy SC. Ethanol toxicity and oxidative stress. (Comment) Toxicol Lett. 1992;63:231–241. doi: 10.1016/0378-4274(92)90086-Y. [DOI] [PubMed] [Google Scholar]
  56. Boon AC, Vos AP, Graus YM, Rimmelzwaan GF, Osterhaus AD. In vitro effect of bioactive compounds on influenza virus specific B- and T-cell responses. Scand J Immunol. 2002;55(1):24–32. doi: 10.1046/j.1365-3083.2002.01014.x. [DOI] [PubMed] [Google Scholar]
  57. Borregaard N, Jensen HS, Bjerrum OW. Prevention of tissue damage: inhibition of myeloperoxidase mediated inactivation of alpha 1-proteinase inhibitor by N-acetyl cysteine, glutathione, and methionine. Agents Actions. 1987;22(3–4):255–260. doi: 10.1007/BF02009054. [DOI] [PubMed] [Google Scholar]
  58. Bostom AG, Shemin D, Yoburn D, Fisher DH, Nadeau MR, Selhub J. Lack of effect of oral N-acetylcysteine on the acute dialysis-related lowering of total plasma homocysteine in hemodialysis patients. Atherosclerosis. 1996;120(1–2):241–244. doi: 10.1016/0021-9150(95)05705-6. [DOI] [PubMed] [Google Scholar]
  59. Bounous G. Whey protein concentrate (WPC) and glutathione modulation in cancer treatment. Anticancer Res. 2000;20(6C):4785–4792. [PubMed] [Google Scholar]
  60. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA. 1995;274(13):1049–1057. doi: 10.1001/jama.1995.03530130055028. [DOI] [PubMed] [Google Scholar]
  61. Bowles WH, Goral V. Clinical trial of the anti-plaque activity of a mucolytic agent, N-acetyl cysteine. Dent Hyg (Chic) 1985;59(10):454–456. [PubMed] [Google Scholar]
  62. Bray GP, Mowat C, Muir DF, Tredger JM, Williams R. The effect of chronic alcohol intake on prognosis and outcome in paracetamol overdose. Hum Exp Toxicol. 1991;10(6):435–438. doi: 10.1177/096032719101000612. [DOI] [PubMed] [Google Scholar]
  63. Breitkreutz R, Holm S, Pittack N, Beichert M, Babylon A, Yodoi J, Droge W. Massive loss of sulfur in HIV infection. AIDS Res Hum Retrovir. 2000;16(3):203–209. doi: 10.1089/088922200309296. [DOI] [PubMed] [Google Scholar]
  64. Breitkreutz R, Pittack N, Nebe CT, Schuster D, Brust J, Beichert M, Hack V, Daniel V, Edler L, Droge W. Improvement of immune functions in HIV infection by sulfur supplementation: two randomized trials. J Mol Med. 2000;78(1):55–62. doi: 10.1007/s001099900073. [DOI] [PubMed] [Google Scholar]
  65. Briganti S, Wlaschek M, Hinrichs C, Bellei B, Flori E, Treiber N, Iben S, Picardo M, Scharffetter-Kochanek K. Small molecular antioxidants effectively protect from PUVA-induced oxidative stress responses underlying fibroblast senescence and photoaging. Free Radic Biol Med. 2008;45(5):636–644. doi: 10.1016/j.freeradbiomed.2008.05.006. [DOI] [PubMed] [Google Scholar]
  66. Briguori C, Manganelli F, Scarpato P, Elia PP, Golia B, Riviezzo G, Lepore S, Librera M, Villari B, Colombo A, Ricciardelli B. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol. 2002;40(2):298–303. doi: 10.1016/S0735-1097(02)01958-7. [DOI] [PubMed] [Google Scholar]
  67. Brocard H, Charpin J, Germouty J. Multicenter, double-blind study of oral acetylcysteine vs. placebo. Eur J Respir Dis Suppl. 1980;111:65–69. [PubMed] [Google Scholar]
  68. Brok J, Buckley N, Gluud C. Interventions for paracetamol (acetaminophen) overdoses. Cochrane Database Syst Rev. 2002;3:CD003328. doi: 10.1002/14651858.CD003328. [DOI] [PubMed] [Google Scholar]
  69. Bromley PN, Cottam SJ, Hilmi I, Tan KC, Heaton N, Ginsburg R, Potter DR. Effects of intraoperative N-acetylcysteine in orthotopic liver transplantation. Br J Anaesth. 1995;75(3):352–354. doi: 10.1093/bja/75.3.352. [DOI] [PubMed] [Google Scholar]
  70. Broughan TA, Soloway RD. Acetaminophen hepatoxicity. Dig Dis Sci. 2000;45(8):1553–1558. doi: 10.1023/A:1005508910222. [DOI] [PubMed] [Google Scholar]
  71. Brown L, Rimm EB, Seddon JM, Giovannucci EL, Chasan-Taber L, Spiegelman D, Willett WC, Hankinson SE. A prospective study of carotenoid intake and risk of cataract extraction in US men. Am J Clin Nutr. 1999;70(4):517–524. doi: 10.1093/ajcn/70.4.517. [DOI] [PubMed] [Google Scholar]
  72. Buckley NA, Whyte IM, O’Connell DL, Dawson AH. Oral or intravenous N-acetylcysteine: which is the treatment of choice for acetaminophen (paracetamol) poisoning? J Toxicol Clin Toxicol. 1999;37(6):759–767. doi: 10.1081/CLT-100102453. [DOI] [PubMed] [Google Scholar]
  73. Buhl R, Holroyd KJ, Mastrangeli A, Cantin AM, Jaffe HA, Wells FB, Saltini C, Crystal RG. Systemic glutathione deficiency in symptom-free HIV-seropositive individuals. Lancet. 1989;334:1294–1298. doi: 10.1016/S0140-6736(89)91909-0. [DOI] [PubMed] [Google Scholar]
  74. Burgunder JM, Varriale A, Lauterburg BH. Effect of N-acetylcysteine on plasma cysteine and glutathione following paracetamol administration. Eur J Clin Pharmacol. 1989;36(2):127–131. doi: 10.1007/BF00609183. [DOI] [PubMed] [Google Scholar]
  75. Bylin G, Hedenstierna G, Lagerstrand L, Wagner PD. No influence of acetylcysteine on gas exchange and spirometry in chronic asthma. Eur J Respir Dis. 1987;71(2):102–107. [PubMed] [Google Scholar]
  76. Cantin AM, Hubbard RC, Crystal RG. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract in idiopathic pulmonary fibrosis. Am Rev Respir Dis. 1989;139:370–372. doi: 10.1164/ajrccm/139.2.370. [DOI] [PubMed] [Google Scholar]
  77. Casagrande S, Bonetto V, Fratelli M, Gianazza E, Eberini I, Massignan T, Salmona M, Chang G, Holmgren A, Ghezzi P. Glutathionylation of human thioredoxin: a possible crosstalk between the glutathione and thioredoxin systems. Proc Natl Acad Sci U S A. 2002;99(15):9745–9749. doi: 10.1073/pnas.152168599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Castagna A, Legrazie C, Accordini A, Giulidori P, Cavalli G, Bottiglieri T, Lazzarin A. Cerebrospinal fluid S-adenosylmethionine (SAMe) and glutathione concentrations in HIV infection: effect of parenteral treatment with SAMe. Neurology. 1995;45(9):1678–1683. doi: 10.1212/WNL.45.9.1678. [DOI] [PubMed] [Google Scholar]
  79. Cayota A, Vuillier F, Gonzalez G, Dighiero G. In vitro antioxidant treatment recovers proliferative responses of anergic CD4+ lymphocytes from human immunodeficiency virus-infected individuals. Blood. 1996;87(11):4746–4753. [PubMed] [Google Scholar]
  80. Chasan-Taber L, Willett WC, Seddon JM, Stampfer MJ, Rosner B, Colditz GA, Speizer FE, Hankinson SE. A prospective study of carotenoid and vitamin A intakes and risk of cataract extraction in US women. Am J Clin Nutr. 1999;70(4):509–516. doi: 10.1093/ajcn/70.4.509. [DOI] [PubMed] [Google Scholar]
  81. Chiao JW, Chung FL, Kancherla R, Ahmed T, Mittelman A, Conaway CC. Sulforaphane and its metabolite mediate growth arrest and apoptosis in human prostate cancer cells. Int J Oncol. 2002;20(3):631–636. doi: 10.3892/ijo.20.3.631. [DOI] [PubMed] [Google Scholar]
  82. Chikina S, Iagmurov B, Kopylev ID, Soodaeva SK, Chuchalin AG. N-Acetylcysteine: low and high doses in the treatment of chronic obstructive lung diseases in Chernobyl accident liquidators. Ter Arkh. 2002;74(3):62–65. [PubMed] [Google Scholar]
  83. Childs A, Jacobs C, Kaminski T, Halliwell B, Leeuwenburgh C. Supplementation with vitamin C and N-acetyl-cysteine increases oxidative stress in humans after an acute muscle injury induced by eccentric exercise. Free Radic Biol Med. 2001;31(6):745–753. doi: 10.1016/S0891-5849(01)00640-2. [DOI] [PubMed] [Google Scholar]
  84. Choudhary G, Dudley SC., Jr Heart failure, oxidative stress, and ion channel modulation. Congest Heart Fail. 2002;8(3):148–155. doi: 10.1111/j.1527-5299.2002.00716.x. [DOI] [PubMed] [Google Scholar]
  85. Christman BW, Bernard GR. Antilipid mediator and antioxidant therapy in adult respiratory distress syndrome. New Horiz. 1993;1(4):623–630. [PubMed] [Google Scholar]
  86. Clotet B, Gomez M, Ruiz L, Sirera G, Romeu J. Lack of short-term efficacy of N-acetyl-L-cysteine in human immunodeficiency virus-positive patients with CD4 cell counts <250/mm(3) {Letter} J Acquir Immun Defic Syndr Hum Retrovirol. 1995;9(1):98–99. doi: 10.1097/00042560-199505010-00015. [DOI] [PubMed] [Google Scholar]
  87. Cogo A, Chieffo A, Farinatti M, Ciaccia A. Efficacy of topical tuaminoheptane combined with N-acetyl-cysteine in reducing nasal resistance. A double-blind rhinomanometric study versus xylometazoline and placebo. Arzneimittelforschung. 1996;46(4):385–388. [PubMed] [Google Scholar]
  88. Cotgreave IA, Goldschmidt L, Tonkonogi M, Svensson M. Differentiation-specific alterations to glutathione synthesis in and hormonally stimulated release from human skeletal muscle cells. FASEB J. 2002;16(3):435–437. doi: 10.1096/fj.01-0685fje. [DOI] [PubMed] [Google Scholar]
  89. Coyle LC, Rodriguez A, Jeschke RE, Simon-Lee A, Abbott KC, Taylor AJ. Acetylcysteine in diabetes (AID): a randomized study of acetylcysteine for the prevention of contrast nephropathy in diabetics. Am Heart J. 2006;151(5):1032.e9–1032.e12. doi: 10.1016/j.ahj.2006.02.002. [DOI] [PubMed] [Google Scholar]
  90. Daily D, Vlamis-Gardikas A, Offen D, Mittelman L, Melamed E, Holmgren A, Barzilai A. Glutaredoxin protects cerebellar granule neurons from dopamine-induced apoptosis by activating NF-kappa B via Ref-1. J Biol Chem. 2001;276(2):1335–1344. doi: 10.1074/jbc.M008121200. [DOI] [PubMed] [Google Scholar]
  91. Davidson SD, Milanesa DM, Mallouh C, Choudhury MS, Tazaki H, Konno S. A possible regulatory role of glyoxalase I in cell viability of human prostate cancer. Urol Res. 2002;30(2):116–121. doi: 10.1007/s00240-002-0244-7. [DOI] [PubMed] [Google Scholar]
  92. Davies SJ, Reichardt-Pascal SY, Vaughan D, Russell GI. Differential effect of ischaemia-reperfusion injury on anti-oxidant enzyme activity in the rat kidney. Exp Nephrol. 1995;3(6):348–354. [PubMed] [Google Scholar]
  93. Davis M. Protective agents for acetaminophen overdose. Semin Liver Dis. 1986;6(2):138–147. doi: 10.1055/s-2008-1040597. [DOI] [PubMed] [Google Scholar]
  94. De Backer WA, Amsel B, Jorens PG, Bossaert L, Hiemstra PS, van Noort P, van Overveld FJ. N-acetylcysteine pretreatment of cardiac surgery patients influences plasma neutrophil elastase and neutrophil influx in bronchoalveolar lavage fluid. Intensive Care Med. 1996;22(9):900–908. doi: 10.1007/BF02044114. [DOI] [PubMed] [Google Scholar]
  95. De Flora S, Grassi C, Carati L. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. Eur Respir J. 1997;10(7):1535–1541. doi: 10.1183/09031936.97.10071535. [DOI] [PubMed] [Google Scholar]
  96. De Mattia G, Bravi MC, Laurenti O, Cassone-Faldetta M, Armiento A, Ferri C, Balsano F. Influence of reduced glutathione infusion on glucose metabolism in patients with non-insulin-dependent diabetes mellitus. Metabolism. 1998;47(8):993–997. doi: 10.1016/S0026-0495(98)90357-2. [DOI] [PubMed] [Google Scholar]
  97. De Mattia G, Bravi MC, Laurenti O, Cassone-Faldetta M, Proietti A, De Luca O, Armiento A, Ferri C. Reduction of oxidative stress by oral N-acetyl-L-cysteine treatment decreases plasma soluble vascular cell adhesion molecule-1 concentrations in non-obese, non-dyslipidaemic, normotensive, patients with non-insulin-dependent diabetes. Diabetologia. 1998;41(11):1392–1396. doi: 10.1007/s001250051082. [DOI] [PubMed] [Google Scholar]
  98. de Quay B, Malinverni R, Lauterburg BH. Glutathione depletion in HIV-infected patients: role of cysteine deficiency and effect of oral N-acetylcysteine. AIDS. 1992;6(8):815–819. doi: 10.1097/00002030-199208000-00008. [DOI] [PubMed] [Google Scholar]
  99. De Roos FJ, Hoffman RS. Drug-induced hepatotoxicity. N Engl J Med. 1996;334(13):863. doi: 10.1056/NEJM199603283341313. [DOI] [PubMed] [Google Scholar]
  100. De Rosa SC, Zaretsky MD, Dubs JG, Roederer M, Anderson M, Green A, Mitra D, Watanabe N, Nakamura H, Tjioe I, Deresinski SC, Moore WA, Ela SW, Parks D, Herzenberg LA. N-acetylcysteine replenishes glutathione in HIV infection. Eur J Clin Investig. 2000;30(10):915–929. doi: 10.1046/j.1365-2362.2000.00736.x. [DOI] [PubMed] [Google Scholar]
  101. De Stefano N, Matthews PM, Ford B, Genge A, Karpati G, Arnold DL. Short-term dichloroacetate treatment improves indices of cerebral metabolism in patients with mitochondrial disorders. Neurology. 1995;45(6):1193–1198. doi: 10.1212/WNL.45.6.1193. [DOI] [PubMed] [Google Scholar]
  102. Dean BS, Bricker JD, Krenzelok EP. Outpatient N-acetylcysteine treatment for acetaminophen poisoning: an ethical dilemma or a new financial mandate? Vet Hum Toxicol. 1996;38(3):222–224. [PubMed] [Google Scholar]
  103. Demirturk L, Yazgan Y, Tarcin O, Ozel M, Diler M, Oncul O, Yildirim S. Does N-acetyl cystein affect the sensitivity and specificity of Helicobacter pylori stool antigen test? Helicobacter. 2003;8(2):120–123. doi: 10.1046/j.1523-5378.2003.00132.x. [DOI] [PubMed] [Google Scholar]
  104. Di Bisceglie AM. Hepatitis C. Lancet. 1998;351(9099):351–355. doi: 10.1016/S0140-6736(97)07361-3. [DOI] [PubMed] [Google Scholar]
  105. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial) Am J Cardiol. 2002;89(3):356–358. doi: 10.1016/S0002-9149(01)02243-3. [DOI] [PubMed] [Google Scholar]
  106. Dick CA, Brown DM, Donaldson K, Stone V. The role of free radicals in the toxic and inflammatory effects of four different ultrafine particle types. Inhal Toxicol. 2003;15(1):39–52. doi: 10.1080/08958370304454. [DOI] [PubMed] [Google Scholar]
  107. Dincer Y, Akcay T, Konukogku D, Hatemi H. Erythrocyte susceptibility to lipid peroxidation in patients with coronary atherosclerosis. Acta Med Okayama. 1999;53(6):259–264. doi: 10.18926/AMO/31620. [DOI] [PubMed] [Google Scholar]
  108. Domenighetti G, Suter PM, Schaller MD, Ritz R, Perret C. Treatment with N-acetylcysteine during acute respiratory distress syndrome: a randomized, double-blind, placebo-controlled clinical study. J Crit Care. 1997;12(4):177–182. doi: 10.1016/S0883-9441(97)90029-0. [DOI] [PubMed] [Google Scholar]
  109. Drager LF, Andrade L, Barros de Toledo JF, Laurindo FR, Machado Cesar LA, Seguro AC. Renal effects of N-acetylcysteine in patients at risk for contrast nephropathy: decrease in oxidant stress-mediated renal tubular injury. Nephrol Dial Transplant. 2004;19(7):1803–1807. doi: 10.1093/ndt/gfh261. [DOI] [PubMed] [Google Scholar]
  110. Droge W, Breitkreutz R. N-acetyl-cysteine in the therapy of HIV-positive patients. Curr Opin Clin Nutr Metab Care. 1999;2(6):493–498. doi: 10.1097/00075197-199911000-00011. [DOI] [PubMed] [Google Scholar]
  111. Droge W, Breitkreutz R. Glutathione and immune function. Proc Nutr Soc. 2000;59(4):595–600. doi: 10.1017/S0029665100000847. [DOI] [PubMed] [Google Scholar]
  112. Droge W, Eck H-P, Gmunder H, Mihm S. Modulation of lymphocyte functions and immune responses by cysteine and cysteine derivatives. Am J Med. 1991;91(Suppl. 3C):140S–144S. doi: 10.1016/0002-9343(91)90297-B. [DOI] [PubMed] [Google Scholar]
  113. Droge W, Eck H-P, Naher H, Pekar U, Daniel V. Abnormal amino-acid concentrations in the blood of patients with acquired immunodeficiency syndrome (AIDS) may contribute to the immunological deficit. Biol Chem Hoppe Seyler. 1988;369:143–148. doi: 10.1515/bchm3.1988.369.1.143. [DOI] [PubMed] [Google Scholar]
  114. Droge W, Eck HP, Mihm S. HIV-induced cysteine deficiency and T-cell dysfunction – a rationale for treatment with N-acetylcysteine. Immunol Today. 1992;13(6):211–214. doi: 10.1016/0167-5699(92)90156-2. [DOI] [PubMed] [Google Scholar]
  115. Dueholm M, Nielsen C, Thorshauge H, Evald T, Hansen NC, Madsen HD, Maltbaek N. N-acetylcysteine by metered dose inhaler in the treatment of chronic bronchitis: a multi-centre study. Respir Med. 1992;86(2):89–92. doi: 10.1016/S0954-6111(06)80220-9. [DOI] [PubMed] [Google Scholar]
  116. Durham JD, Caputo C, Dokko J, Zaharakis T, Pahlavan M, Keltz J, Dutka P, Marzo K, Maesaka JK, Fishbane S. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int. 2002;62(6):2202–2207. doi: 10.1046/j.1523-1755.2002.00673.x. [DOI] [PubMed] [Google Scholar]
  117. Efrati S, Dishy V, Averbukh M, Blatt A, Krakover R, Weisgarten J, Morrow JD, Stein MC, Golik A. The effect of N-acetylcysteine on renal function, nitric oxide, and oxidative stress after angiography. Kidney Int. 2003;64(6):2182–2187. doi: 10.1046/j.1523-1755.2003.00322.x. [DOI] [PubMed] [Google Scholar]
  118. Ekberg-Jansson A, Larson M, MacNee W, Tunek A, Wahlgren L, Wouters EF, Larsson S. N-isobutyrylcysteine, a donor of systemic thiols, does not reduce the exacerbation rate in chronic bronchitis. Eur Respir J. 1999;13(4):829–834. doi: 10.1034/j.1399-3003.1999.13d22.x. [DOI] [PubMed] [Google Scholar]
  119. Eklund A, Eriksson O, Hakansson L, Larsson K, Ohlsson K, Venge P, Bergstrand H, Bjornson A, Brattsand R, Glennow C, et al. Oral N-acetylcysteine reduces selected humoral markers of inflammatory cell activity in BAL fluid from healthy smokers: correlation to effects on cellular variables. Eur Respir J. 1988;1(9):832–838. [PubMed] [Google Scholar]
  120. Eren N, Cakir O, Oruc A, Kaya Z, Erdinc L. Effects of N-acetylcysteine on pulmonary function in patients undergoing coronary artery bypass surgery with cardiopulmonary bypass. Perfusion. 2003;18(6):345–350. doi: 10.1191/0267659103pf696oa. [DOI] [PubMed] [Google Scholar]
  121. Estensen RD, Levy M, Klopp SJ, Galbraith AR, Mandel JS, Blomquist JA, Wattenberg LW. N-acetylcysteine suppression of the proliferative index in the colon of patients with previous adenomatous colonic polyps. Cancer Lett. 1999;147(1–2):109–114. doi: 10.1016/S0304-3835(99)00281-5. [DOI] [PubMed] [Google Scholar]
  122. Estevez AG, Jordan J. Nitric oxide and superoxide, a deadly cocktail. Ann N Y Acad Sci. 2002;962:207–211. doi: 10.1111/j.1749-6632.2002.tb04069.x. [DOI] [PubMed] [Google Scholar]
  123. Evald T, Hansen M, Balslov S, Brorson-Riis L, Hansen NC, Maltbaek N, Thorshauge H. Steroid response after long-term treatment with oral N-acetylcysteine in patients with chronic obstructive bronchitis. Ugeskr Laeger. 1989;151(46):2076–2078. [PubMed] [Google Scholar]
  124. Eylar E, Rivera-Quinones C, Molina C, Baez I, Molina F, Mercado CM. N-acetylcysteine enhances T cell functions and T cell growth in culture. Int Immunol. 1993;5(1):97–101. doi: 10.1093/intimm/5.1.97. [DOI] [PubMed] [Google Scholar]
  125. Fechner A, Bohme C, Gromer S, Funk M, Schirmer R, Becker K. Antioxidant status and nitric oxide in the malnutrition syndrome kwashiorkor. Pediatr Res. 2001;49(2):237–243. doi: 10.1203/00006450-200102000-00018. [DOI] [PubMed] [Google Scholar]
  126. Ferrari V. Safety and drug interactions of oral acetylcysteine related to utilization data. Eur J Respir Dis Suppl. 1980;111:151–157. [PubMed] [Google Scholar]
  127. Ferrari V, Spinelli W. Life table analysis of long-term randomised trials in pneumology – a worked example and a plea. Eur J Respir Dis Suppl. 1980;110:227–236. [PubMed] [Google Scholar]
  128. Fischer UM, Tossios P, Huebner A, Geissler HJ, Bloch W, Mehlhorn U. Myocardial apoptosis prevention by radical scavenging in patients undergoing cardiac surgery. J Thorac Cardiovasc Surg. 2004;128(1):103–108. doi: 10.1016/j.jtcvs.2003.11.034. [DOI] [PubMed] [Google Scholar]
  129. Flescher E, Ledbetter JA, Schieven GL, Velaroch N, Fossum D, Dang H, Ogawa N, Talal N. Longitudinal exposure of human T lymphocytes to weak oxidative stress suppresses transmembrane and nuclear signal transduction. J Immunol. 1994;153(11):4880–4889. [PubMed] [Google Scholar]
  130. Fontana RJ, McCashland TM, Benner KG, Appelman HD, Gunartanam NT, Wisecarver JL, Rabkin JM, Lee WM. Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation. The Acute Liver Failure Study Group. Liver Transpl Surg. 1999;5(6):480–484. doi: 10.1002/lt.500050607. [DOI] [PubMed] [Google Scholar]
  131. Freudenthaler SM, Schreeb KH, Wiese A, Pilz J, Gleiter CH. Influence of controlled hypoxia and radical scavenging agents on erythropoietin and malondialdehyde concentrations in humans. Acta Physiol Scand. 2002;174(3):231–235. doi: 10.1046/j.1365-201x.2002.00946.x. [DOI] [PubMed] [Google Scholar]
  132. Friedman AN, Bostom AG, Laliberty P, Selhub J, Shemin D. The effect of N-acetylcysteine on plasma total homocysteine levels in hemodialysis: a randomized, controlled study. Am J Kidney Dis. 2003;41(2):442–446. doi: 10.1053/ajkd.2003.50054. [DOI] [PubMed] [Google Scholar]
  133. Fulghesu AM, Ciampelli M, Muzj G, Belosi C, Selvaggi L, Ayala GF, Lanzone A. N-acetyl-cysteine treatment improves insulin sensitivity in women with polycystic ovary syndrome. Fertil Steril. 2002;77(6):1128–1135. doi: 10.1016/S0015-0282(02)03133-3. [DOI] [PubMed] [Google Scholar]
  134. Furst DE, Clements PJ, Harris R, Ross M, Levy J, Paulus HE. Measurement of clinical change in progressive systemic sclerosis: a 1 year double-blind placebo-controlled trial of N-acetylcysteine. Ann Rheum Dis. 1979;38(4):356–361. doi: 10.1136/ard.38.4.356. [DOI] [PMC free article] [PubMed] [Google Scholar]
  135. Galli F, Floridi A, Buoncristiani U. Oxidant stress in hemodialysis patients. Contrib Nephrol. 2002;137:371–378. doi: 10.1159/000060264. [DOI] [PubMed] [Google Scholar]
  136. Ghezzi P, Romines B, Fratelli M, Eberini I, Gianazza E, Casagrande S, Laragione T, Mengozzi M, Herzenberg LA. Protein glutathionylation: coupling and uncoupling of glutathione to protein thiol groups in lymphocytes under oxidative stress and HIV infection. Mol Immunol. 2002;38(10):773–780. doi: 10.1016/S0161-5890(01)00114-6. [DOI] [PubMed] [Google Scholar]
  137. Gillissen A, Nowak D. Characterization of N-acetylcysteine and ambroxol in anti-oxidant therapy. Respir Med. 1998;92(4):609–623. doi: 10.1016/S0954-6111(98)90506-6. [DOI] [PubMed] [Google Scholar]
  138. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Diabetes mellitus and risk of prostate cancer (United States) Cancer Causes Control. 1998;9(1):3–9. doi: 10.1023/A:1008822917449. [DOI] [PubMed] [Google Scholar]
  139. Gisolf EH, Dreezen C, Danner SA, Weel JL, Weverling GJ. Risk factors for hepatotoxicity in HIV-1-infected patients receiving ritonavir and saquinavir with or without stavudine. Prometheus Study Group. Clin Infect Dis. 2000;31(5):1234–1239. doi: 10.1086/317449. [DOI] [PubMed] [Google Scholar]
  140. Gladyshev VN, Jeang KT, Stadtman TC. Selenocysteine, identified as the penultimate C-terminal residue in human T-cell thioredoxin reductase, corresponds to TGA in the human placental gene. Proc Natl Acad Sci U S A. 1996;93(12):6146–6151. doi: 10.1073/pnas.93.12.6146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  141. Gladyshev VN, Khangulov SV, Stadtman TC. Properties of the selenium- and molybdenum-containing nicotinic acid hydroxylase from Clostridium barkeri. Biochemistry. 1996;35(1):212–223. doi: 10.1021/bi951793i. [DOI] [PubMed] [Google Scholar]
  142. Golden MH, Ramdath D. Free radicals in the pathogenesis of kwashiorkor. Proc Nutr Soc. 1987;46(1):53–68. doi: 10.1079/PNS19870008. [DOI] [PubMed] [Google Scholar]
  143. Goldenberg I, Shechter M, Matetzky S, Jonas M, Adam M, Pres H, Elian D, Agranat O, Schwammenthal E, Guetta V. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature. Eur Heart J. 2004;25(3):212–218. doi: 10.1016/j.ehj.2003.11.011. [DOI] [PubMed] [Google Scholar]
  144. Gotoh Y, Noda T, Iwakiri R, Fujimoto K, Rhoads CA, Aw TY. Lipid peroxide-induced redox imbalance differentially mediates CaCo-2 cell proliferation and growth arrest. Cell Prolif. 2002;35(4):221–235. doi: 10.1046/j.1365-2184.2002.00241.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  145. Gotz M, Kraemer R, Kerrebijn KF, Popow C. Oral acetylcysteine in cystic fibrosis. A co-operative study. Eur J Respir Dis Suppl. 1980;111:122–126. [PubMed] [Google Scholar]
  146. Gow AJ, Chen Q, Hess DT, Day BJ, Ischiropoulos H, Stamler JS. Basal and stimulated protein S-nitrosylation in multiple cell types and tissues. J Biol Chem. 2002;277(12):9637–9640. doi: 10.1074/jbc.C100746200. [DOI] [PubMed] [Google Scholar]
  147. Graber R, Farine JC, Fumagalli I, Tatti V, Losa GA. Apoptosis and oxidative status in peripheral blood mononuclear cells of diabetic patients. Apoptosis. 1999;4(4):263–270. doi: 10.1023/A:1026408409916. [DOI] [PubMed] [Google Scholar]
  148. Grandjean EM, Berthet P, Ruffmann R, Leuenberger P. Cost-effectiveness analysis of oral N-acetylcysteine as a preventive treatment in chronic bronchitis. Pharmacol Res. 2000;42(1):39–50. doi: 10.1006/phrs.1999.0647. [DOI] [PubMed] [Google Scholar]
  149. Grant PR, Black A, Garcia N, Prieto J, Garson JA. Combination therapy with interferon-alpha plus N-acetyl cysteine for chronic hepatitis C: a placebo controlled double-blind multicentre study. J Med Virol. 2000;61(4):439–442. doi: 10.1002/1096-9071(200008)61:4&#x0003c;439::AID-JMV5&#x0003e;3.0.CO;2-L. [DOI] [PubMed] [Google Scholar]
  150. Grassi C. Long-term oral acetylcysteine in chronic bronchitis. A double-blind controlled study. Eur J Respir Dis Suppl. 1980;111:93–108. [PubMed] [Google Scholar]
  151. Grassi C, Morandini GC. A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis. Eur J Clin Pharmacol. 1976;09(5–6):393–396. doi: 10.1007/BF00606554. [DOI] [PubMed] [Google Scholar]
  152. Grattagliano I, Vendemiale G, Sabba C, Buonamico P, Altomare E. Oxidation of circulating proteins in alcoholics: role of acetaldehyde and xanthine oxidase. J Hepatol. 1996;25(1):28–36. doi: 10.1016/S0168-8278(96)80324-2. [DOI] [PubMed] [Google Scholar]
  153. Gringhuis SI, Leow A, Papendrecht-van der Voort EAM, Remans PHJ, Breedveld FC, Verweij CL. Displacement of linker for activation of T cells from the plasma membrane due to redox balance alterations results in hyporesponsiveness of synovial fluid T lymphocytes in rheumatoid arthritis. J Immunol. 2000;164(4):2170–2179. doi: 10.4049/jimmunol.164.4.2170. [DOI] [PubMed] [Google Scholar]
  154. Grundman M. Vitamin E and Alzheimer disease: the basis for additional clinical trials. Am J Clin Nutr. 2000;71(2):630S–636S. doi: 10.1093/ajcn/71.2.630s. [DOI] [PubMed] [Google Scholar]
  155. Guan X, Hoffman BN, McFarland DC, Gilkerson KK, Dwivedi C, Erickson AK, Bebensee S, Pellegrini J. Glutathione and mercapturic acid conjugates of sulofenur and their activity against a human colon cancer cell line. Drug Metab Dispos. 2002;30(3):331–335. doi: 10.1124/dmd.30.3.331. [DOI] [PubMed] [Google Scholar]
  156. Hammarqvist F, Luo JL, Cotgreave IA, Andersson K, Wernerman J. Skeletal muscle glutathione is depleted in critically ill patients. Crit Care Med. 1997;25(1):78–84. doi: 10.1097/00003246-199701000-00016. [DOI] [PubMed] [Google Scholar]
  157. Hansen NC, Skriver A, Brorsen-Riis L, Balslov S, Evald T, Maltbaek N, Gunnersen G, Garsdal P, Sander P, Pedersen JZ, et al. Orally administered N-acetylcysteine may improve general well-being in patients with mild chronic bronchitis. Respir Med. 1994;88(7):531–535. doi: 10.1016/S0954-6111(05)80337-3. [DOI] [PubMed] [Google Scholar]
  158. Hansen RM, Csuka ME, McCarty DJ, Saryan LA. Gold induced aplastic anemia. Complete response to corticosteroids, plasmapheresis, and N-acetylcysteine infusion. J Rheumatol. 1985;12(4):794–797. [PubMed] [Google Scholar]
  159. Hansen RM, Varma RR, Hanson GA. Gold induced hepatitis and pure red cell aplasia. Complete recovery after corticosteroid and N-acetylcysteine therapy. J Rheumatol. 1991;18(8):1251–1253. [PubMed] [Google Scholar]
  160. Harrison PM, Keays R, Bray GP, Alexander GJ, Williams R. Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet. 1990;335(8705):1572–1573. doi: 10.1016/0140-6736(90)91388-Q. [DOI] [PubMed] [Google Scholar]
  161. Harrison PM, Wendon JA, Gimson AE, Alexander GJ, Williams R. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med. 1991;324(26):1852–1857. doi: 10.1056/NEJM199106273242604. [DOI] [PubMed] [Google Scholar]
  162. Hauer K, Hildebrandt W, Sehl Y, Edler L, Oster P, Droge W. Improvement in muscular performance and decrease in tumor necrosis factor level in old age after antioxidant treatment. J Mol Med. 2003;81(2):118–125. doi: 10.1007/s00109-002-0406-7. [DOI] [PubMed] [Google Scholar]
  163. Heinig JH, Pedersen B, Andersen I, Dalgaard CE, Rasmussen O, Weeke ER, Enk B. The mucolytic effects of acetylcysteine compared with bromhexine and a placebo in patients with chronic bronchitis. Ugeskr Laeger. 1985;147(46):3694–3697. [PubMed] [Google Scholar]
  164. Helbling B, von Overbeck J, Lauterburg BH. Decreased release of glutathione into the systemic circulation of patients with HIV infection. Eur J Clin Investig. 1996;26(1):38–44. doi: 10.1046/j.1365-2362.1996.88237.x. [DOI] [PubMed] [Google Scholar]
  165. Henderson A, Hayes P. Acetylcysteine as a cytoprotective antioxidant in patients with severe sepsis: potential new use for an old drug. Ann Pharmacother. 1994;28(9):1086–1088. doi: 10.1177/106002809402800914. [DOI] [PubMed] [Google Scholar]
  166. Herzenberg LA, De Rosa SC, Dubs JG, Roederer M, Anderson MT, Ela SW, Deresinski SC. Glutathione deficiency is associated with impaired survival in HIV disease. Proc Natl Acad Sci U S A. 1997;94(5):1967–1972. doi: 10.1073/pnas.94.5.1967. [DOI] [PMC free article] [PubMed] [Google Scholar]
  167. Hitchins AD, McDonough FE, Wells PA. The use of Escherichia coli mutants to measure the bioavailability of essential amino acids in foods. Plant Foods Hum Nutr. 1989;39(1):109–120. doi: 10.1007/BF01092407. [DOI] [PubMed] [Google Scholar]
  168. Hoffer ME, Kopke RD, Weisskopf P, Gottshall K, Allen K, Wester D. Microdose gentamicin administration via the round window microcatheter: results in patients with Meniere’s disease. Ann N Y Acad Sci. 2001;942:46–51. doi: 10.1111/j.1749-6632.2001.tb03734.x. [DOI] [PubMed] [Google Scholar]
  169. Hogan JC, Lewis MJ, Henderson AH. Glyceryl trinitrate and platelet aggregation: effects of N-acetyl-cysteine. Br J Clin Pharmacol. 1989;27(5):617–619. doi: 10.1111/j.1365-2125.1989.tb03425.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  170. Hogan JC, Lewis MJ, Henderson AH. N-acetylcysteine fails to attenuate haemodynamic tolerance to glyceryl trinitrate in healthy volunteers. Br J Clin Pharmacol. 1989;28(4):421–426. doi: 10.1111/j.1365-2125.1989.tb03522.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  171. Hogan JC, Lewis MJ, Henderson AH. Chronic administration of N-acetylcysteine fails to prevent nitrate tolerance in patients with stable angina pectoris. Br J Clin Pharmacol. 1990;30(4):573–577. doi: 10.1111/j.1365-2125.1990.tb03815.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  172. Holmgren A. Thioredoxin. Annu Rev Biochem. 1985;54:237–271. doi: 10.1146/annurev.bi.54.070185.001321. [DOI] [PubMed] [Google Scholar]
  173. Holmgren A. Thioredoxin and glutaredoxin systems. J Biol Chem. 1989;264(24):13963–13966. [PubMed] [Google Scholar]
  174. Holroyd KJ, Buhl R, Borok Z, Roum JH, Bokser AD, Grimes GJ, Czerski D, Cantin AM, Crystal RG. Correction of glutathione deficiency in the lower respiratory tract of HIV seropositive individuals by glutathione aerosol treatment. Thorax. 1993;48(10):985–989. doi: 10.1136/thx.48.10.985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  175. Holt S, Goodler D, Marley R, Patch D, Burroughs A, Fernando B, Harry D, Moore K. Improvement in renal function in hepatorenal syndrome with N-acetylcysteine [letter] Lancet. 1999;353(9149):294–295. doi: 10.1016/S0140-6736(05)74933-3. [DOI] [PubMed] [Google Scholar]
  176. Holt S, Marley R, Fernando B, Harry D, Anand R, Goodier D, Moore K. Acute cholestasis-induced renal failure: effects of antioxidants and ligands for the thromboxane A2 receptor. Kidney Int. 1999;55(1):271–277. doi: 10.1046/j.1523-1755.1999.00252.x. [DOI] [PubMed] [Google Scholar]
  177. Horowitz JD, Henry CA, Syrjanen ML, Louis WJ, Fish RD, Antman EM, Smith TW. Nitroglycerine/N-acetylcysteine in the management of unstable angina pectoris. Eur Heart J. 1988;9(Suppl A):95–100. doi: 10.1093/eurheartj/9.suppl_A.95. [DOI] [PubMed] [Google Scholar]
  178. Horowitz JD, Henry CA, Syrjanen ML, Louis WJ, Fish RD, Smith TW, Antman EM. Combined use of nitroglycerin and N-acetylcysteine in the management of unstable angina pectoris. Circulation. 1988;77(4):787–794. doi: 10.1161/01.CIR.77.4.787. [DOI] [PubMed] [Google Scholar]
  179. Hortin GL, Landt M, Powderly WG. Changes in plasma amino acid concentrations in response to HIV-1 infection. Clin Chem. 1994;40:785–789. [PubMed] [Google Scholar]
  180. Huengsberg M, Waring R, Moffitt D, Round R, Winer J, Gompels M, Shahmanesh M. Serum cysteine levels in HIV infection. {LETTER, COMMENT} AIDS. 1998;12(10):1245. doi: 10.1097/00002030-199810000-00018. [DOI] [PubMed] [Google Scholar]
  181. Hultberg B, Andersson A, Isaksson A. Interaction of metals and thiols in cell damage and glutathione distribution: potentiation of mercury toxicity by dithiothreitol. Toxicology. 2001;156(2–3):93–100. doi: 10.1016/S0300-483X(00)00331-0. [DOI] [PubMed] [Google Scholar]
  182. Hurd RW, Wilder BJ, Helveston WR, Uthman BM. Treatment of four siblings with progressive myoclonus epilepsy of the Unverricht-Lundborg type with N-acetylcysteine. Neurology. 1996;47(5):1264–1268. doi: 10.1212/WNL.47.5.1264. [DOI] [PubMed] [Google Scholar]
  183. Hursting SD, Shen JC, Sun XY, Wang TT, Phang JM, Perkins SN. Modulation of cyclophilin gene expression by N-4-(hydroxyphenyl)retinamide: association with reactive oxygen species generation and apoptosis. Mol Carcinog. 2002;33(1):16–24. doi: 10.1002/mc.10020. [DOI] [PubMed] [Google Scholar]
  184. Iantomasi T, Marraccini P, Favilli F, Vincenzini MT, Ferretti P, Tonelli F. Glutathione metabolism in Crohn’s disease. Biochem Med Metab Biol. 1994;53(2):87–91. doi: 10.1006/bmmb.1994.1062. [DOI] [PubMed] [Google Scholar]
  185. Iversen HK. N-acetylcysteine enhances nitroglycerin-induced headache and cranial arterial responses. Clin Pharmacol Ther. 1992;52(2):125–133. doi: 10.1038/clpt.1992.121. [DOI] [PubMed] [Google Scholar]
  186. Jackson AA. Blood glutathione in severe malnutrition in childhood. Trans R Soc Trop Med Hyg. 1986;80(6):911–913. doi: 10.1016/0035-9203(86)90256-7. [DOI] [PubMed] [Google Scholar]
  187. Jackson IM, Barnes J, Cooksey P. Efficacy and tolerability of oral acetylcysteine (Fabrol) in chronic bronchitis: a double-blind placebo controlled study. J Int Med Res. 1984;12(3):198–206. doi: 10.1177/030006058401200312. [DOI] [PubMed] [Google Scholar]
  188. Jahoor F, Jackson A, Gazzard B, Philips G, Sharpstone D, Frazer ME, Heird W. Erythrocyte glutathione deficiency in symptom-free HIV infection is associated with decreased synthesis rate. Am J Phys. 1999;276(1 Pt 1):E205–E211. doi: 10.1152/ajpendo.1999.276.1.E205. [DOI] [PubMed] [Google Scholar]
  189. Jain SK, Krueger KS, McVie R, Jaramillo JJ, Palmer M, Smith T. Relationship of blood thromboxane-B2 (TxB2) with lipid peroxides and effect of vitamin E and placebo supplementation on TxB2 and lipid peroxide levels in type 1 diabetic patients. Diabetes Care. 1998;21(9):1511–1516. doi: 10.2337/diacare.21.9.1511. [DOI] [PubMed] [Google Scholar]
  190. Jain SK, Lim G. Lipoic acid decreases lipid peroxidation and protein glycosylation and increases (Na(+) + K(+))- and Ca(++)-ATPase activities in high glucose-treated human erythrocytes. Free Radic Biol Med. 2000;29(11):1122–1128. doi: 10.1016/S0891-5849(00)00410-X. [DOI] [PubMed] [Google Scholar]
  191. Jain SK, McVie R. Hyperketonemia can increase lipid peroxidation and lower glutathione levels in human erythrocytes in vitro and in type 1 diabetic patients. Diabetes. 1999;48(9):1850–1855. doi: 10.2337/diabetes.48.9.1850. [DOI] [PubMed] [Google Scholar]
  192. Jain SK, McVie R, Jaramillo JJ, Palmer M, Smith T. Effect of modest vitamin E supplementation on blood glycated hemoglobin and triglyceride levels and red cell indices in type I diabetic patients. J Am Coll Nutr. 1996;15(5):458–461. doi: 10.1080/07315724.1996.10718624. [DOI] [PubMed] [Google Scholar]
  193. Jain SK, McVie R, Jaramillo JJ, Palmer M, Smith T, Meachum ZD, Little RL. The effect of modest vitamin E supplementation on lipid peroxidation products and other cardiovascular risk factors in diabetic patients. Lipids. 1996;31(Suppl):87–90. doi: 10.1007/BF02637057. [DOI] [PubMed] [Google Scholar]
  194. Jain SK, McVie R, Smith T. Vitamin E supplementation restores glutathione and malondialdehyde to normal concentrations in erythrocytes of type 1 diabetic children. Diabetes Care. 2000;23(9):1389–1394. doi: 10.2337/diacare.23.9.1389. [DOI] [PubMed] [Google Scholar]
  195. James JS. Stanford NAC study: glutathione level predicts survival. AIDS Treat News. 1997;266:1–5. [PubMed] [Google Scholar]
  196. James LP, Wells E, Beard RH, Farrar HC. Predictors of outcome after acetaminophen poisoning in children and adolescents. J Pediatr. 2002;140(5):522–526. doi: 10.1067/mpd.2002.122936. [DOI] [PubMed] [Google Scholar]
  197. Jeannin P, Delneste Y, Lecoanet-Henchoz S, Gauchat J-F, Life P, Holmes D, Bonnefoy J-Y. Thiols decrease human interleukin (IL) 4 production and IL-4-induced immunoglobulin synthesis. J Exp Med. 1995;182(6):1785–1792. doi: 10.1084/jem.182.6.1785. [DOI] [PMC free article] [PubMed] [Google Scholar]
  198. Jepsen S, Herlevsen P, Knudsen P, Bud MI, Klausen NO. Antioxidant treatment with N-acetylcysteine during adult respiratory distress syndrome: a prospective, randomized, placebo-controlled study. Crit Care Med. 1992;20(7):918–923. doi: 10.1097/00003246-199207000-00004. [DOI] [PubMed] [Google Scholar]
  199. Jepsen S, Klaerke A, Nielsen PH, Nielsen ST, Simonsen O. Systemic administration of N-acetylcysteine has no effect on postoperative lung function following elective upper laparotomy in lung healthy patients. Acta Anaesthesiol Scand. 1989;33(3):219–222. doi: 10.1111/j.1399-6576.1989.tb02894.x. [DOI] [PubMed] [Google Scholar]
  200. Johnston SC, Pelletier LL., Jr Enhanced hepatotoxicity of acetaminophen in the alcoholic patient. Two case reports and a review of the literature. Medicine (Baltimore) 1997;76(3):185–191. doi: 10.1097/00005792-199705000-00004. [DOI] [PubMed] [Google Scholar]
  201. Jones A. Over-the-counter analgesics: a toxicology perspective. Am J Ther. 2002;9(3):245–257. doi: 10.1097/00045391-200205000-00010. [DOI] [PubMed] [Google Scholar]
  202. Julius M, Lang CA, Gleiberman L, Harburg E, DiFranceisco W, Schork A. Glutathione and morbidity in a community-based sample of elderly. J Clin Epidemiol. 1994;47(9):1021–1026. doi: 10.1016/0895-4356(94)90117-1. [DOI] [PubMed] [Google Scholar]
  203. Kanner SB, Damle NK, Blake J, Aruffo A, Ledbetter JA. CD2/LFA-3 ligation induces phospholipase-C gamma 1 tyrosine phosphorylation and regulates CD3 signaling. J Immunol. 1992;148(7):2023–2029. [PubMed] [Google Scholar]
  204. Kanner SB, Deans JP, Ledbetter JA. Regulation of CD3-induced phospholipase C-gamma 1 (PLC gamma 1) tyrosine phosphorylation by CD4 and CD45 receptors. Immunology. 1992;75(3):441–447. [PMC free article] [PubMed] [Google Scholar]
  205. Kanner SB, Kavanagh TJ, Grossmann A, Hu SL, Bolen JB, Rabinovitch PS, Ledbetter JA. Sulfhydryl oxidation down-regulates T-cell signaling and inhibits tyrosine phosphorylation of phospholipase C gamma 1. Proc Natl Acad Sci U S A. 1992;89(1):300–304. doi: 10.1073/pnas.89.1.300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  206. Kanner SB, Ledbetter JA. CD45 regulates TCR-induced signalling through tyrosine phosphorylation of phospholipase C gamma 1. Biochem Soc Trans. 1992;20(1):178–184. doi: 10.1042/bst0200178. [DOI] [PubMed] [Google Scholar]
  207. Kasielski M, Nowak D. Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. Respir Med. 2001;95(6):448–456. doi: 10.1053/rmed.2001.1066. [DOI] [PubMed] [Google Scholar]
  208. Katsinelos P, Kountouras J, Paroutoglou G, Beltsis A, Mimidis K, Zavos C. Intravenous N-acetylcysteine does not prevent post-ERCP pancreatitis. Gastrointest Endosc. 2005;62(1):105–111. doi: 10.1016/S0016-5107(05)01574-9. [DOI] [PubMed] [Google Scholar]
  209. Kay J, Chow WH, Chan TM, Lo SK, Kwok OH, Yip A, Fan K, Lee CH, Lam WF. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. JAMA. 2003;289(5):553–558. doi: 10.1001/jama.289.5.553. [DOI] [PubMed] [Google Scholar]
  210. Kearns GL. Acetaminophen poisoning in children: treat early and long enough. J Pediatr. 2002;140(5):495–498. doi: 10.1067/mpd.2002.124592. [DOI] [PubMed] [Google Scholar]
  211. Kearns GL, Leeder JS, Wasserman GS. Acetaminophen intoxication during treatment: what you don’t know can hurt you. Clin Pediatr (Phila) 2000;39(3):133–144. doi: 10.1177/000992280003900301. [DOI] [PubMed] [Google Scholar]
  212. Keays R, Harrison PM, Wendon JA, Forbes A, Gove C, Alexander GJ, Williams R. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ. 1991;303(6809):1026–1029. doi: 10.1136/bmj.303.6809.1026. [DOI] [PMC free article] [PubMed] [Google Scholar]
  213. Kefer JM, Hanet CE, Boitte S, Wilmotte L, De Kock M. Acetylcysteine, coronary procedure and prevention of contrast-induced worsening of renal function: which benefit for which patient? Acta Cardiol. 2003;58(6):555–560. doi: 10.2143/AC.58.6.2005321. [DOI] [PubMed] [Google Scholar]
  214. Kelly FJ. Gluthathione: in defence of the lung. Food Chem Toxicol. 1999;37(9–10):963–966. doi: 10.1016/S0278-6915(99)00087-3. [DOI] [PubMed] [Google Scholar]
  215. Kerr F, Dawson A, Whyte IM, Buckley N, Murray L, Graudins A, Chan B, Trudinger B. The Australasian Clinical Toxicology Investigators Collaboration randomized trial of different loading infusion rates of N-acetylcysteine. Ann Emerg Med. 2005;45(4):402–408. doi: 10.1016/j.annemergmed.2004.08.040. [DOI] [PubMed] [Google Scholar]
  216. Kes P. Hyperhomocysteinemia in end-stage renal failure. Acta Med Croatica. 2000;54(4–5):175–181. [PubMed] [Google Scholar]
  217. Kiefer P, Vogt J, Radermacher P. From mucolytic to antioxidant and liver protection: new aspects in the intensive care unit career of N-acetylcysteine. Crit Care Med. 2000;28(12):3935–3936. doi: 10.1097/00003246-200012000-00037. [DOI] [PubMed] [Google Scholar]
  218. Kim HJ, Liu X, Wang H, Kohyama T, Kobayashi T, Wen FQ, Romberger DJ, Abe S, MacNee W, Rahman I, Rennard SI. Glutathione prevents inhibition of fibroblast-mediated collagen gel contraction by cigarette smoke. Am J Physiol Lung Cell Mol Physiol. 2002;283(2):L409–L417. doi: 10.1152/ajplung.00059.2002. [DOI] [PubMed] [Google Scholar]
  219. Kinnunen J, Pietila J, Ahovuo J, Mankinen P, Tervahartiala P. Double contrast barium meal and acetylcysteine. Eur J Radiol. 1989;9(4):258–259. [PubMed] [Google Scholar]
  220. Knapen MFCM, Mulder TPJ, Van Rooij IALM, Peters WHM, Steegers EAP. Low whole blood glutathione levels in pregnancies complicated by preeclampsia or the hemolysis, elevated liver enzymes, low platelets syndrome. Obstet Gynecol. 1998;92(6):1012–1015. doi: 10.1016/s0029-7844(98)00333-0. [DOI] [PubMed] [Google Scholar]
  221. Koechlin C, Couillard A, Simar D, Cristol JP, Bellet H, Hayot M, Prefaut C. Does oxidative stress alter quadriceps endurance in chronic obstructive pulmonary disease? Am J Respir Crit Care Med. 2004;169(9):1022–1027. doi: 10.1164/rccm.200310-1465OC. [DOI] [PubMed] [Google Scholar]
  222. Kokcam I, Naziroglu M. Antioxidants and lipid peroxidation status in the blood of patients with psoriasis. Clin Chim Acta. 1999;289(1–2):23–31. doi: 10.1016/S0009-8981(99)00150-3. [DOI] [PubMed] [Google Scholar]
  223. Konrad F, Schoenberg MH, Wiedmann H, Kilian J, Georgieff M. The application of n-acetylcysteine as an antioxidant and mucolytic in mechanical ventilation in intensive care patients. A prospective, randomized, placebo-controlled, double-blind study. Anaesthesist. 1995;44(9):651–658. doi: 10.1007/s001010050200. [DOI] [PubMed] [Google Scholar]
  224. Konukoglu D, Akcay T, Dincer Y, Hatemi H. The susceptibility of red blood cells to autoxidation in type 2 diabetic patients with angiopathy. Metabolism. 1999;48(12):1481–1484. doi: 10.1016/S0026-0495(99)90233-0. [DOI] [PubMed] [Google Scholar]
  225. Konukoglu D, Hatemi H, Ozer EM, Gonen S, Akcay T. The erythrocyte glutathione levels during oral glucose tolerance test. J Endocrinol Investig. 1997;20(8):471–475. doi: 10.1007/BF03348003. [DOI] [PubMed] [Google Scholar]
  226. Kopke R, Allen KA, Henderson D, Hoffer M, Frenz D, Van de Water T. A radical demise. Toxins and trauma share common pathways in hair cell death. Ann N Y Acad Sci. 1999;884:171–191. doi: 10.1111/j.1749-6632.1999.tb08641.x. [DOI] [PubMed] [Google Scholar]
  227. Kopke RD, Coleman JK, Liu J, Campbell KC, Riffenburgh RH. Candidate’s thesis: enhancing intrinsic cochlear stress defenses to reduce noise-induced hearing loss. Laryngoscope. 2002;112(9):1515–1532. doi: 10.1097/00005537-200209000-00001. [DOI] [PubMed] [Google Scholar]
  228. Kopke RD, Hoffer ME, Wester D, O’Leary MJ, Jackson RL. Targeted topical steroid therapy in sudden sensorineural hearing loss. Otol Neurotol. 2001;22(4):475–479. doi: 10.1097/00129492-200107000-00011. [DOI] [PubMed] [Google Scholar]
  229. Kopke RD, Weisskopf PA, Boone JL, Jackson RL, Wester DC, Hoffer ME, Lambert DC, Charon CC, Ding DL, McBride D. Reduction of noise-induced hearing loss using L-NAC and salicylate in the chinchilla. Hear Res. 2000;149(1–2):138–146. doi: 10.1016/S0378-5955(00)00176-3. [DOI] [PubMed] [Google Scholar]
  230. Krenzelok EP. New developments in the therapy of intoxications. Toxicol Lett. 2002;127(1–3):299–305. doi: 10.1016/S0378-4274(01)00512-4. [DOI] [PubMed] [Google Scholar]
  231. Kretzschmar M, Pfeiffer L, Schmidt C, Schirrmeister W. Plasma levels of glutathione, alpha-tocopherol and lipid peroxides in polytraumatized patients; evidence for a stimulating effect of TNF alpha on glutathione synthesis. Exp Toxicol Pathol. 1998;50(4–6):477–483. doi: 10.1016/S0940-2993(98)80037-7. [DOI] [PubMed] [Google Scholar]
  232. Kupczyk M, Kuna P. Mucolytics in acute and chronic respiratory tract disorders. II. Uses for treatment and antioxidant properties. Pol Merkuriusz Lek. 2002;12(69):248–252. [PubMed] [Google Scholar]
  233. Lamson DW, Brignall MS. The use of nebulized glutathione in the treatment of emphysema: a case report [In Process Citation] Altern Med Rev. 2000;5(5):429–431. [PubMed] [Google Scholar]
  234. Lands LC, Grey VL, Grenier C. Total plasma antioxidant capacity in cystic fibrosis. Pediatr Pulmonol. 2000;29(2):81–87. doi: 10.1002/(SICI)1099-0496(200002)29:2&#x0003c;81::AID-PPUL1&#x0003e;3.0.CO;2-N. [DOI] [PubMed] [Google Scholar]
  235. Lang CA, Naryshkin S, Schnieder DL, Mills BJ, Lindeman RD. Low blood glutathione in healthy aging adults. J Lab Clin Med. 1992;120(5):720–725. [PubMed] [Google Scholar]
  236. LaRowe SD, Mardikian P, Malcolm R, Myrick H, Kalivas P, McFarland K, Saladin M, McRae A, Brady K. Safety and tolerability of N-acetylcysteine in cocaine-dependent individuals. Am J Addict. 2006;15(1):105–110. doi: 10.1080/10550490500419169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  237. Larrauri A, Fabra R, Gomez-Lechon MJ, Trullenque R, Castell JV. Toxicity of paracetamol in human hepatocytes. Comparison of the protective effects of sulfhydryl compounds acting as glutathione precursors. Mol Toxicol. 1987;1(4):301–311. [PubMed] [Google Scholar]
  238. Larsen LC, Fuller SH. Management of acetaminophen toxicity. Am Fam Physician. 1996;53(1):185–190. [PubMed] [Google Scholar]
  239. Laurent T, Markert M, Feihl F, Schaller MD, Perret C. Oxidant-antioxidant balance in granulocytes during ARDS. Effect of N-acetylcysteine. Chest. 1996;109(1):163–166. doi: 10.1378/chest.109.1.163. [DOI] [PubMed] [Google Scholar]
  240. Lauterburg BH, Corcoran GB, Mitchell JR. Mechanism of action of N-acetylcysteine in the protection against the hepatotoxicity of acetaminophen in rats in vivo. J Clin Invest. 1983;71(4):980–991. doi: 10.1172/JCI110853. [DOI] [PMC free article] [PubMed] [Google Scholar]
  241. Lauterburg BH, Velez ME. Glutathione deficiency in alcoholics: risk factor for paracetamol hepatotoxicity. Gut. 1988;29:1153–1157. doi: 10.1136/gut.29.9.1153. [DOI] [PMC free article] [PubMed] [Google Scholar]
  242. Lee WM. Drug-induced hepatotoxicity. Aliment Pharmacol Ther. 1993;7(5):477–485. doi: 10.1111/j.1365-2036.1993.tb00123.x. [DOI] [PubMed] [Google Scholar]
  243. Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 1995;333(17):1118–1127. doi: 10.1056/NEJM199510263331706. [DOI] [PubMed] [Google Scholar]
  244. Lee WM. Management of acute liver failure. Semin Liver Dis. 1996;16(4):369–378. doi: 10.1055/s-2007-1007250. [DOI] [PubMed] [Google Scholar]
  245. Lenhartz H, Ndasi R, Anninos A, Botticher D, Mayatepek E, Tetanye E, Leichsenring M. The clinical manifestation of the kwashiorkor syndrome is related to increased lipid peroxidation. J Pediatr. 1998;132(5):879–881. doi: 10.1016/S0022-3476(98)70324-5. [DOI] [PubMed] [Google Scholar]
  246. Listed NA. Acetylcysteine (Parvolex) for paracetamol poisoning. Drug Ther Bull. 1980;18(21):81–82. [PubMed] [Google Scholar]
  247. Listed NA. N-acetylcysteine. Altern Med Rev. 2000;5(5):467–471. [PubMed] [Google Scholar]
  248. Loguercio C, Nardi G, Argenzio F, Aurilio C, Petrone E, Grella A, Del Vecchio Blanco C, Coltorti M. Effect of S-adenosyl-L-methionine administration on red blood cell cysteine and glutathione levels in alcoholic patients with and without liver disease. Alcohol Alcohol. 1994;29(5):597–604. [PubMed] [Google Scholar]
  249. Lou MF, Dickerson JE, Jr, Tung WH, Wolfe JK, Chylack LT., Jr Correlation of nuclear color and opalescence with protein S-thiolation in human lenses. Exp Eye Res. 1999;68(5):547–552. doi: 10.1006/exer.1998.0638. [DOI] [PubMed] [Google Scholar]
  250. Louwerse ES, Weverling GJ, Bossuyt PM, Meyjes FE, de Jong JM. Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch Neurol. 1995;52(6):559–564. doi: 10.1001/archneur.1995.00540300031009. [DOI] [PubMed] [Google Scholar]
  251. Lyons L, Studdiford JS, Sommaripa AM. Treatment of acetaminophen overdosage with N-acetylcysteine. N Engl J Med. 1977;296(3):174–175. doi: 10.1056/NEJM197701202960315. [DOI] [PubMed] [Google Scholar]
  252. MacNeill BDHS, Bazari H, Patton KK, Colon-Hernadez P, DeJoseph D, Jang IK. Prophylaxis of contrast-induced nephropathy in patients undergoing coronary angiography. Catheter Cardiovas Interv. 2003;60(4):458–461. doi: 10.1002/ccd.10684. [DOI] [PubMed] [Google Scholar]
  253. Macy AM. Preventing hepatotoxicity in acetaminophen overdose. Am J Nurs. 1979;79(2):301–303. [PubMed] [Google Scholar]
  254. Mangione S, Patel DD, Levin BR, Fiel SB. Erythrocytic glutathione in cystic fibrosis. A possible marker of pulmonary dysfunction. Chest. 1994;105(5):1470–1473. doi: 10.1378/chest.105.5.1470. [DOI] [PubMed] [Google Scholar]
  255. Marenzi G, Assanelli E, Marana I, Lauri G, Campodonico J, Grazi M, De Metrio M, Galli S, Fabbiocchi F, Montorsi P, Veglia F, Bartorelli AL. N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. N Engl J Med. 2006;354(26):2773–2782. doi: 10.1056/NEJMoa054209. [DOI] [PubMed] [Google Scholar]
  256. Marini U, Visconti G, Spotti D, Geniram A. Controlled endoscopic study on gastroduodenal safety of acetylcysteine after oral administration. Eur J Respir Dis Suppl. 1980;111:147–150. [PubMed] [Google Scholar]
  257. Marquardt ED. Treatment of acetaminophen toxicity. Am J Hosp Pharm. 1977;34(8):805–806. [PubMed] [Google Scholar]
  258. Marshall RJ, Scott KC, Hill RC, Lewis DD, Sundstrom D, Jones GL, Harper J. Supplemental vitamin C appears to slow racing greyhounds. J Nutr. 2002;132(6 Suppl 2):1616S–1621S. doi: 10.1093/jn/132.6.1616S. [DOI] [PubMed] [Google Scholar]
  259. Martin DS, Willis SE, Cline DM. N-acetylcysteine in the treatment of human arsenic poisoning. J Am Board Fam Pract. 1990;3(4):293–296. [PubMed] [Google Scholar]
  260. Marui N, Offermann MK, Swerlick R, Kunsch C, Rosen CA, Ahmad M, Alexander RW, Medford RM. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. J Clin Invest. 1993;92(4):1866–1874. doi: 10.1172/JCI116778. [DOI] [PMC free article] [PubMed] [Google Scholar]
  261. Maurer WG, Zeisler J (1978) Intravenous acetylcysteine as treatment for acetaminophen overdose. Am J Hosp Pharm 35(9):1025, 1030 [PubMed]
  262. Maurice MM, Nakamura H, van der Voort EAM, van Vliet AI, Staal FJT, Tak P-P, Breedveld FC, Verweij CL. Evidence for the role of an altered redox state in hyporesponsiveness of synovial T cells in rheumatoid arthritis. J Immunol. 1997;158(3):1458–1465. [PubMed] [Google Scholar]
  263. Mayaud C, Lentschner C, Bouchoucha S, Marsac J. Thiamphenicol glycinate acetylcysteinate in the treatment of acute respiratory infections with mucostasis. Eur J Respir Dis Suppl. 1980;111:70–73. [PubMed] [Google Scholar]
  264. McGavin C. Oral N-acetylcysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. British Thoracic Society Research Committee. Thorax. 1985;40(11):832–835. doi: 10.1136/thx.40.11.832. [DOI] [PMC free article] [PubMed] [Google Scholar]
  265. McKay DL, Perrone G, Rasmussen H, Dallal G, Hartman W, Cao G, Prior RL, Roubenoff R, Blumberg JB. The effects of a multivitamin/mineral supplement on micronutrient status, antioxidant capacity and cytokine production in healthy older adults consuming a fortified diet. J Am Coll Nutr. 2000;19(5):613–621. doi: 10.1080/07315724.2000.10718959. [DOI] [PubMed] [Google Scholar]
  266. Medved I, Brown MJ, Bjorksten AR, Leppik JA, Sostaric S, McKenna MJ. N-acetylcysteine infusion alters blood redox status but not time to fatigue during intense exercise in humans. J Appl Physiol. 2003;94(4):1572–1582. doi: 10.1152/japplphysiol.00884.2002. [DOI] [PubMed] [Google Scholar]
  267. Medved I, Brown MJ, Bjorksten AR, McKenna MJ. Effects of intravenous N-acetylcysteine infusion on time to fatigue and potassium regulation during prolonged cycling exercise. J Appl Physiol. 2004;96(1):211–217. doi: 10.1152/japplphysiol.00458.2003. [DOI] [PubMed] [Google Scholar]
  268. Medved I, Brown MJ, Bjorksten AR, Murphy KT, Petersen AC, Sostaric S, Gong X, McKenna MJ. N-acetylcysteine enhances muscle cysteine and glutathione availability and attenuates fatigue during prolonged exercise in endurance-trained individuals. J Appl Physiol. 2004;97:1477. doi: 10.1152/japplphysiol.00371.2004. [DOI] [PubMed] [Google Scholar]
  269. Meister A, Anderson ME, Hwang O. Intracellular cysteine and glutathione delivery systems. J Am Coll Nutr. 1986;5(2):137–151. doi: 10.1080/07315724.1986.10720121. [DOI] [PubMed] [Google Scholar]
  270. Melillo G, Chiummariello A, Scala G. On the use of a new molecular combination of acetylcysteine with thiamphenicol glycinate in bronchopulmonary suppurations. G Ital Chemioter. 1966;13(1):156–160. [PubMed] [Google Scholar]
  271. Meyer A, Buhl R, Kampf S, Magnussen H. Intravenous N-acetylcysteine and lung glutathione of patients with pulmonary fibrosis and normals. Am J Respir Crit Care Med. 1995;152(3):1055–1060. doi: 10.1164/ajrccm.152.3.7663783. [DOI] [PubMed] [Google Scholar]
  272. Meyer A, Buhl R, Magnussen H. The effect of oral N-Acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis. Eur Respir J. 1994;7(3):431–436. doi: 10.1183/09031936.94.07030431. [DOI] [PubMed] [Google Scholar]
  273. Michelet F, Gueguen R, Leroy P, Wellman M, Nicolas A, Siest G. Blood and plasma glutathione measured in healthy subjects by HPLC: relation to sex, aging, biological variables, and life habits. Clin Chem. 1995;41(10):1509–1517. [PubMed] [Google Scholar]
  274. Milewski J, Rydzewska G, Degowska M, Kierzkiewicz M, Rydzewski A. N-acetylcysteine does not prevent post-endoscopic retrograde cholangiopancreatography hyperamylasemia and acute pancreatitis. World J Gastroenterol. 2006;12(23):3751–3755. doi: 10.3748/wjg.v12.i23.3751. [DOI] [PMC free article] [PubMed] [Google Scholar]
  275. Millar AB, Pavia D, Agnew JE, Lopez-Vidriero MT, Lauque D, Clarke SW. Effect of oral N-acetylcysteine on mucus clearance. Br J Dis Chest. 1985;79(3):262–266. doi: 10.1016/0007-0971(85)90046-4. [DOI] [PubMed] [Google Scholar]
  276. Miller LF, Rumack BH. Clinical safety of high oral doses of acetylcysteine. Semin Oncol. 1983;10(1 Suppl 1):76–85. [PubMed] [Google Scholar]
  277. Miller M. Clinical experimentation using a combination with antibiotic and mucolytic activity in the treatment of respiratory and oto-rhino-laryngologic infections with allergic components. Brux Med. 1975;55(6):349–351. [PubMed] [Google Scholar]
  278. Miralles-Barrachina O, Savoye G, Belmonte-Zalar L, Hochain P, Ducrotte P, Hecketsweiler B, Lerebours E, Dechelotte P. Low levels of glutathione in endoscopic biopsies of patients with Crohn’s colitis: the role of malnutrition. Clin Nutr. 1999;18(5):313–317. doi: 10.1016/S0261-5614(98)80030-7. [DOI] [PubMed] [Google Scholar]
  279. Mitchell JR, Corcoran GB, Smith CV, Hughes H, Lauterburg BH. Alkylation and peroxidation injury from chemically reactive metabolites. Adv Exp Med Biol. 1981;136(Pt A):199–223. doi: 10.1007/978-1-4757-0674-1_12. [DOI] [PubMed] [Google Scholar]
  280. Mitchell JR, Thorgeirsson SS, Potter WZ, Jollow DJ, Keiser H. Acetaminophen-induced hepatic injury: protective role of glutathione in man and rationale for therapy. Clin Pharmacol Ther. 1974;16(4):676–684. doi: 10.1002/cpt1974164676. [DOI] [PubMed] [Google Scholar]
  281. Moberly JB, Logan J, Borum PR, Story KO, Webb LE, Jassal SV, Mupas L, Rodela H, Alghamdi GA, Moran JE, Wolfson M, Martis L, Oreopoulos DG. Elevation of whole-blood glutathione in peritoneal dialysis patients by L-2-oxothiazolidine-4-carboxylate, a cysteine prodrug (Procysteine(R)) J Am Soc Nephrol. 1998;9(6):1093–1099. doi: 10.1681/ASN.V961093. [DOI] [PubMed] [Google Scholar]
  282. Molnar Z, MacKinnon KL, Shearer E, Lowe D, Watson ID. The effect of N-acetylcysteine on total serum anti-oxidant potential and urinary albumin excretion in critically ill patients. Intensive Care Med. 1998;24(3):230–235. doi: 10.1007/s001340050555. [DOI] [PubMed] [Google Scholar]
  283. Molnar Z, Shearer E, Lowe D. N-Acetylcysteine treatment to prevent the progression of multisystem organ failure: a prospective, randomized, placebo-controlled study. Crit Care Med. 1999;27(6):1100–1104. doi: 10.1097/00003246-199906000-00028. [DOI] [PubMed] [Google Scholar]
  284. Molnar Z, Szakmany T, Koszegi T. Prophylactic N-acetylcysteine decreases serum CRP but not PCT levels and microalbuminuria following major abdominal surgery. A prospective, randomised, double-blinded, placebo-controlled clinical trial. Intensive Care Med. 2003;29(5):749–755. doi: 10.1007/s00134-003-1723-1. [DOI] [PubMed] [Google Scholar]
  285. Montanini S, Sinardi D, Pratico C, Sinardi AU, Trimarchi G. Use of acetylcysteine as the life-saving antidote in Amanita phalloides (Death cap) poisoning – case report on 11 patients. Arzneim Forsch Drug Res. 1999;49(12):1044–1047. doi: 10.1055/s-0031-1300549. [DOI] [PubMed] [Google Scholar]
  286. Moriuchi H, Zaha M, Fukumoto T, Yuizono T. Activation of polymorphonuclear leukocytes in oleic acid-induced lung injury. Intensive Care Med. 1998;24(7):709–715. doi: 10.1007/s001340050649. [DOI] [PubMed] [Google Scholar]
  287. Morrison JA, Jacobsen DW, Sprecher DL, Robinson K, Khoury P, Daniels SR. Serum glutathione in adolescent males predicts parental coronary heart disease. Circulation. 1999;100(22):2244–2247. doi: 10.1161/01.CIR.100.22.2244. [DOI] [PubMed] [Google Scholar]
  288. Moss M, Guidot DM, Wong-Lambertina M, Ten Hoor T, Perez RL, Brown LAS. The effects of chronic alcohol abuse on pulmonary glutathione homeostasis. Am J Respir Crit Care Med. 2000;161(2):414–419. doi: 10.1164/ajrccm.161.2.9905002. [DOI] [PubMed] [Google Scholar]
  289. Murakami K, Kondo T, Ohtsuka Y, Fujiwara Y, Shimada M, Kawakami Y. Impairment of glutathione metabolism in erthrocytes from patients with diabetes mellitus. Metab Clin Exp. 1989;38:753–758. doi: 10.1016/0026-0495(89)90061-9. [DOI] [PubMed] [Google Scholar]
  290. Mutimer D, Neuberger J. Acute liver failure: improving outcome despite a paucity of treatment options. Q J Med. 1993;86(7):409–411. [PubMed] [Google Scholar]
  291. Mutlu-Turkoglu U, Ademoglu E, Ibrahimoglu L, Aykac-Toker G, Uysal M. Imbalance between lipid peroxidation and antioxidant status in preeclampsia. Gynecol Obstet Investig. 1998;46(1):37–40. doi: 10.1159/000009994. [DOI] [PubMed] [Google Scholar]
  292. N’Dow J, Robson CN, Matthews JN, Neal DE, Pearson JP. Reducing mucus production after urinary reconstruction: a prospective randomized trial. J Urol. 2001;165(5):1433–1440. doi: 10.1016/S0022-5347(05)66323-9. [DOI] [PubMed] [Google Scholar]
  293. Nakagawa Y, Akao Y, Morikawa H, Hirata I, Katsu K, Naoe T, Ohishi N, Yagi K. Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines. Life Sci. 2002;70(19):2253–2269. doi: 10.1016/S0024-3205(01)01545-4. [DOI] [PubMed] [Google Scholar]
  294. Nakamura H, De Rosa SC, Yodoi J, Holmgren A, Ghezzi P, Herzenberg LA. Chronic elevation of plasma thioredoxin: Inhibition of chemotaxis and curtailment of life expectancy in AIDS. Proc Natl Acad Sci U S A. 2001;98(5):2688–2693. doi: 10.1073/pnas.041624998. [DOI] [PMC free article] [PubMed] [Google Scholar]
  295. Nakamura H, Masutani H, Yodoi J. Redox imbalance and its control in HIV infection. Antioxid Redox Signal. 2002;4(3):455–464. doi: 10.1089/15230860260196245. [DOI] [PubMed] [Google Scholar]
  296. Nallamothu BK, Shojania KG, Saint S, Hofer TP, Humes HD, Moscucci M, Bates ER. Is acetylcysteine effective in preventing contrast-related nephropathy? A meta-analysis. Am J Med. 2004;117(12):938–947. doi: 10.1016/j.amjmed.2004.06.046. [DOI] [PubMed] [Google Scholar]
  297. Naziroglu M, Cay M. Protective role of intraperitoneally administered vitamin E and selenium on the antioxidative defense mechanisms in rats with diabetes induced by streptozotocin. Biol Trace Elem Res. 2001;79(2):149–159. doi: 10.1385/BTER:79:2:149. [DOI] [PubMed] [Google Scholar]
  298. Nielsen HB. N-acetylcysteine. Ugeskr Laeger. 1999;161(31):4424. [PubMed] [Google Scholar]
  299. Nielsen HB, Kharazmi A, Bolbjerg ML, Poulsen HE, Pedersen BK, Secher NH. N-acetylcysteine attenuates oxidative burst by neutrophils in response to ergometer rowing with no effect on pulmonary gas exchange. Int J Sports Med. 2001;22(4):256–260. doi: 10.1055/s-2001-13817. [DOI] [PubMed] [Google Scholar]
  300. Nuttall SL, Dunne F, Kendall MJ, Martin U. Age-independent oxidative stress in elderly patients with non-insulin-dependent diabetes mellitus. QJM. 1999;92(1):33–38. doi: 10.1093/qjmed/92.1.33. [DOI] [PubMed] [Google Scholar]
  301. Oldemeyer JB, Biddle WP, Wurdeman RL, Mooss AN, Cichowski E, Hilleman DE. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography. Am Heart J. 2003;146(6):E23. doi: 10.1016/S0002-8703(03)00511-8. [DOI] [PubMed] [Google Scholar]
  302. Olivieri D, Marsico SA, Del Donno M. Improvement of mucociliary transport in smokers by mucolytics. Eur J Respir Dis Suppl. 1985;139:142–145. [PubMed] [Google Scholar]
  303. Ortolani O, Conti A, De Gaudio AR, Moraldi E, Novelli GP. Glutathione and N-acetylcysteine in the prevention of free-radical damage in the initial phase of septic shock. Recenti Prog Med. 2002;93(2):125–129. [PubMed] [Google Scholar]
  304. Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SH, McCashland TM, Shakil AO, Hay JE, Hynan L, Crippin JS, Blei AT, Samuel G, Reisch J, Lee WM. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137(12):947–954. doi: 10.7326/0003-4819-137-12-200212170-00007. [DOI] [PubMed] [Google Scholar]
  305. Ostapowicz G, Lee WM. Acute hepatic failure: a western perspective. J Gastroenterol Hepatol. 2000;15(5):480–488. doi: 10.1046/j.1440-1746.2000.02074.x. [DOI] [PubMed] [Google Scholar]
  306. Ovesen T, Felding JU, Tommerup B, Schousboe LP, Petersen CG. Effect of N-acetylcysteine on the incidence of recurrence of otitis media with effusion and re-insertion of ventilation tubes. Acta Otolaryngol. 2000;120:79–81. doi: 10.1080/000164800454044. [DOI] [PubMed] [Google Scholar]
  307. Ozaras R, Tahan V, Aydin S, Uzun H, Kaya S, Senturk H. N-acetylcysteine attenuates alcohol-induced oxidative stress in the rat. World J Gastroenterol. 2003;9(1):125–128. doi: 10.3748/wjg.v9.i1.125. [DOI] [PMC free article] [PubMed] [Google Scholar]
  308. Pace BS, Shartava A, Pack-Mabien A, Mulekar M, Ardia A, Goodman SR. Effects of N-acetylcysteine on dense cell formation in sickle cell disease. Am J Hematol. 2003;73(1):26–32. doi: 10.1002/ajh.10321. [DOI] [PubMed] [Google Scholar]
  309. Pacht ER, Diaz P, Clanton T, Hart J, Gadek JE. Alveolar fluid glutathione decreases in asymptomatic HIV-seropositive subjects over time. Chest. 1997;112(3):785–788. doi: 10.1378/chest.112.3.785. [DOI] [PubMed] [Google Scholar]
  310. Pacht ER, Timerman AP, Lykens MG, Merola AJ. Deficiency of alveolar fluid glutathione in patients with sepsis and the adult respiratory distress syndrome. Chest. 1991;100(5):1397–1403. doi: 10.1378/chest.100.5.1397. [DOI] [PubMed] [Google Scholar]
  311. Pannu N, Manns B, Lee H, Tonelli M. Systematic review of the impact of N-acetylcysteine on contrast nephropathy. Kidney Int. 2004;65(4):1366–1374. doi: 10.1111/j.1523-1755.2004.00516.x. [DOI] [PubMed] [Google Scholar]
  312. Parr GD, Huitson A. Oral Fabrol (oral N-acetyl-cysteine) in chronic bronchitis. Br J Dis Chest. 1987;81(4):341–348. doi: 10.1016/0007-0971(87)90182-3. [DOI] [PubMed] [Google Scholar]
  313. Paterson RL, Galley HF, Webster NR. The effect of N-acetylcysteine on nuclear factor-kappa B activation, interleukin-6, interleukin-8, and intercellular adhesion molecule-1 expression in patients with sepsis. Crit Care Med. 2003;31(11):2574–2578. doi: 10.1097/01.ccm.0000089945.69588.18. [DOI] [PubMed] [Google Scholar]
  314. Peake SL, Moran JL, Leppard PI. N-acetyl-L-cysteine depresses cardiac performance in patients with septic shock. Crit Care Med. 1996;24(8):1302–1310. doi: 10.1097/00003246-199608000-00006. [DOI] [PubMed] [Google Scholar]
  315. Pena LR, Hill DB, McClain CJ. Treatment with glutathione precursor decreases cytokine activity. J Parenter Enter Nutr. 1999;23(1):1–6. doi: 10.1177/014860719902300101. [DOI] [PubMed] [Google Scholar]
  316. Pendyala L, Schwartz G, Bolanowska-Higdon W, Hitt S, Zdanowicz J, Murphy M, Lawrence D, Creaven PJ. Phase I/pharmacodynamic study of N-acetylcysteine/oltipraz in smokers: early termination due to excessive toxicity. Cancer Epidemiol Biomark Prev. 2001;10(3):269–272. [PubMed] [Google Scholar]
  317. Perez RS, Zuurmond WW, Bezemer PD, Kuik DJ, van Loenen AC, de Lange JJ, Zuidhof AJ. The treatment of complex regional pain syndrome type I with free radical scavengers: a randomized controlled study. Pain. 2003;102(3):297–307. doi: 10.1016/S0304-3959(02)00414-1. [DOI] [PubMed] [Google Scholar]
  318. Perry HE, Shannon MW. Efficacy of oral versus intravenous N-acetylcysteine in acetaminophen overdose: results of an open-label, clinical trial [see comments] J Pediatr. 1998;132(1):149–152. doi: 10.1016/S0022-3476(98)70501-3. [DOI] [PubMed] [Google Scholar]
  319. Peters WH, Roelofs HM, Hectors MP, Nagengast FM, Jansen JB. Glutathione and glutathione S-transferases in Barrett’s epithelium. Br J Cancer. 1993;67(6):1413–1417. doi: 10.1038/bjc.1993.262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  320. Peterson JD, Herzenberg LA, Vasquez K, Waltenbaugh C. Glutathione levels in antigen-presenting cells modulate Th1 versus Th2 response patterns. Proc Natl Acad Sci U S A. 1998;95(6):3071–3076. doi: 10.1073/pnas.95.6.3071. [DOI] [PMC free article] [PubMed] [Google Scholar]
  321. Peterson RG, Rumack BH. N-acetylcysteine for acetaminophen overdosage (cont.) N Engl J Med. 1977;296(9):515. doi: 10.1056/nejm197703032960914. [DOI] [PubMed] [Google Scholar]
  322. Peterson RG, Rumack BH. Treating acute acetaminophen poisoning with acetylcysteine. JAMA. 1977;237(22):2406–2407. doi: 10.1001/jama.1977.03270490046025. [DOI] [PubMed] [Google Scholar]
  323. Peterson RG, Rumack BH. Toxicity of acetaminophen overdose. J Am Coll Emerg Physicians. 1978;7(5):202–205. doi: 10.1016/S0361-1124(78)80100-2. [DOI] [PubMed] [Google Scholar]
  324. Pineda-Molina E, Klatt P, Vazquez J, Marina A, Garcia de Lacoba M, Perez-Sala D, Lamas S. Glutathionylation of the p50 subunit of NF-kappaB: a mechanism for redox-induced inhibition of DNA binding. Biochemistry. 2001;40(47):14134–14142. doi: 10.1021/bi011459o. [DOI] [PubMed] [Google Scholar]
  325. Ponnappan U. Ubiquitin-proteasome pathway is compromised in CD45RO+ and CD45RA+ T lymphocyte subsets during aging. Exp Gerontol. 2002;37(2–3):359–367. doi: 10.1016/S0531-5565(01)00203-0. [DOI] [PubMed] [Google Scholar]
  326. Porsio A, Borgia M. Intravenous administration of acetylcysteine: clinical experience with its tolerance and action. Clin Ter. 1970;55(2):123–132. [PubMed] [Google Scholar]
  327. Prasad A, Andrews NP, Padder FA, Husain M, Quyyumi AA. Glutathione reverses endothelial dysfunction and improves nitric oxide bioavailability. J Am Coll Cardiol. 1999;34(2):507–514. doi: 10.1016/S0735-1097(99)00216-8. [DOI] [PubMed] [Google Scholar]
  328. Prescott LF. New approaches in managing drug overdosage and poisoning. Br Med J (Clin Res Ed) 1983;287(6387):274–276. doi: 10.1136/bmj.287.6387.274. [DOI] [PMC free article] [PubMed] [Google Scholar]
  329. Prescott LF, Critchley JA. The treatment of acetaminophen poisoning. Annu Rev Pharmacol Toxicol. 1983;23:87–101. doi: 10.1146/annurev.pa.23.040183.000511. [DOI] [PubMed] [Google Scholar]
  330. Prescott LF, Park J, Ballantyne A, Adriaenssens P, Proudfoot AT. Treatment of paracetamol (acetaminophen) poisoning with N- acetylcysteine. Lancet. 1977;2(8035):432–434. doi: 10.1016/S0140-6736(77)90612-2. [DOI] [PubMed] [Google Scholar]
  331. Pulle DF, Glass P, Dulfano MJ. A controlled study of the safety and efficacy of acetylcysteine-isoproterenol combination. Curr Ther Res Clin Exp. 1970;12(8):485–492. [PubMed] [Google Scholar]
  332. Rahman I, Skwarska E, Henry M, Davis M, O’Connor CM, FitzGerald MX, Greening A, MacNee W. Systemic and pulmonary oxidative stress in idiopathic pulmonary fibrosis. Free Radic Biol Med. 1999;27(1–2):60–68. doi: 10.1016/S0891-5849(99)00035-0. [DOI] [PubMed] [Google Scholar]
  333. Rank N, Michel C, Haertel C, Lenhart A, Welte M, Meier-Hellmann A, Spies C. N-acetylcysteine increases liver blood flow and improves liver function in septic shock patients: results of a prospective, randomized, double-blind study. Crit Care Med. 2000;28(12):3799–3807. doi: 10.1097/00003246-200012000-00006. [DOI] [PubMed] [Google Scholar]
  334. Rashid ST, Salman M, Myint F, Baker DM, Agarwal S, Sweny P, Hamilton G. Prevention of contrast-induced nephropathy in vascular patients undergoing angiography: a randomized controlled trial of intravenous N-acetylcysteine. J Vasc Surg. 2004;40(6):1136–1141. doi: 10.1016/j.jvs.2004.09.026. [DOI] [PubMed] [Google Scholar]
  335. Rasmussen JB, Glennow C. Reduction in days of illness after long-term treatment with N-acetylcysteine controlled-release tablets in patients with chronic bronchitis. Eur Respir J. 1988;1(4):351–355. [PubMed] [Google Scholar]
  336. Ratjen F, Wonne R, Posselt HG, Stover B, Hofmann D, Bender SW. A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis. Eur J Pediatr. 1985;144(4):374–378. doi: 10.1007/BF00441781. [DOI] [PubMed] [Google Scholar]
  337. Reid M, Badaloo A, Forrester T, Morlese JF, Frazer M, Heird WC, Jahoor F. In vivo rates of erythrocyte glutathione synthesis in children with severe protein-energy malnutrition. Am J Physiol Endocrinol Metab. 2000;278(3):E405–E412. doi: 10.1152/ajpendo.2000.278.3.E405. [DOI] [PubMed] [Google Scholar]
  338. Reid M, Jahoor F. Glutathione in disease. Curr Opin Clin Nutr Metab Care. 2001;4(1):65–71. doi: 10.1097/00075197-200101000-00012. [DOI] [PubMed] [Google Scholar]
  339. Reinhart K, Spies CD, Meier-Hellmann A, Bredle DL, Hannemann L, Specht M, Schaffartzik W. N-acetylcysteine preserves oxygen consumption and gastric mucosal pH during hyperoxic ventilation. Am J Respir Crit Care Med. 1995;151(3 Pt 1):773–779. doi: 10.1164/ajrccm/151.3_Pt_1.773. [DOI] [PubMed] [Google Scholar]
  340. Repetto M, Reides C, Carretero MLG, Costa M, Griemberg G, Llesuy S. Oxidative stress in blood of HIV infected patients. Clin Chim Acta. 1996;255(2):107–117. doi: 10.1016/0009-8981(96)06394-2. [DOI] [PubMed] [Google Scholar]
  341. Riise GC, Larsson S, Larsson P, Jeansson S, Andersson BA. The intrabronchial microbial flora in chronic bronchitis patients: a target for N-acetylcysteine therapy? Eur Respir J. 1994;7(1):94–101. doi: 10.1183/09031936.94.07010094. [DOI] [PubMed] [Google Scholar]
  342. Ristoff E, Larsson A. Oxidative stress in inborn errors of metabolism: lessons from glutathione deficiency. J Inherit Metab Dis. 2002;25(3):223–226. doi: 10.1023/A:1015634032042. [DOI] [PubMed] [Google Scholar]
  343. Ristoff E, Mayatepek E, Larsson A. Long-term clinical outcome in patients with glutathione synthetase deficiency. J Pediatr. 2001;139(1):79–84. doi: 10.1067/mpd.2001.114480. [DOI] [PubMed] [Google Scholar]
  344. Rizvi SI, Zaid MA. Intracellular reduced glutathione content in normal and type 2 diabetic erythrocytes: effect of insulin and (-)epicatechin. J Physiol Pharmacol. 2001;52(3):483–488. [PubMed] [Google Scholar]
  345. Roederer M, Ela SW, Staal FJT, Herzenberg LA, Herzenberg LA. N-Acetylcysteine: a new approach to anti-HIV therapy. AIDS Res Hum Retroviruses. 1992;8(2):209–217. doi: 10.1089/aid.1992.8.209. [DOI] [PubMed] [Google Scholar]
  346. Roederer M, Staal FJ, Raju PA, Ela SW, Herzenberg LA. Cytokine-stimulated human immunodeficiency virus replication is inhibited by N-acetyl-L-cysteine. Proc Natl Acad Sci U S A. 1990;87(12):4884–4888. doi: 10.1073/pnas.87.12.4884. [DOI] [PMC free article] [PubMed] [Google Scholar]
  347. Roederer M, Staal FJT, Osada H, Herzenberg LA, Herzenberg LA. CD4 and CD8 T cells with high intracellular glutathione levels are selectively lost as the HIV infection progresses. Int Immunol. 1991;3(9):933–937. doi: 10.1093/intimm/3.9.933. [DOI] [PubMed] [Google Scholar]
  348. Roum JH, Borok Z, McElvaney NG, Grimes GJ, Bokser AD, Buhl R, Crystal RG. Glutathione aerosol suppresses lung epithelial surface inflammatory cell-derived oxidants in cystic fibrosis. J Appl Physiol. 1999;87(1):438–443. doi: 10.1152/jappl.1999.87.1.438. [DOI] [PubMed] [Google Scholar]
  349. Roum JH, Buhl R, Mcelvaney NG, Borok Z, Crystal RG. Systemic deficiency of glutathione in cystic fibrosis. J Appl Physiol. 1993;75(6):2419–2424. doi: 10.1152/jappl.1993.75.6.2419. [DOI] [PubMed] [Google Scholar]
  350. Ruan EA, Rao S, Burdick JS, Stryker SJ, Telford GL, Otterson MF, Opara EC, Koch TR. Glutathione levels in chronic inflammatory disorders of the human colon. Nutr Res. 1997;17(3):463–473. doi: 10.1016/S0271-5317(97)00007-9. [DOI] [Google Scholar]
  351. Ruffmann R, Wendel A. GSH rescue by N-acetylcysteine. Klin Wochenschr. 1991;69(18):857–862. doi: 10.1007/BF01649460. [DOI] [PMC free article] [PubMed] [Google Scholar]
  352. Rumack BH. Acetaminophen overdose in young children. Treatment and effects of alcohol and other additional ingestants in 417 cases. Am J Dis Child. 1984;138(5):428–433. doi: 10.1001/archpedi.1984.02140430006003. [DOI] [PubMed] [Google Scholar]
  353. Rumack BH. Acetaminophen overdose in children and adolescents. Pediatr Clin N Am. 1986;33(3):691–701. doi: 10.1016/S0031-3955(16)36050-3. [DOI] [PubMed] [Google Scholar]
  354. Rumack BH. Acetaminophen hepatotoxicity: the first 35 years. J Toxicol Clin Toxicol. 2002;40(1):3–20. doi: 10.1081/CLT-120002882. [DOI] [PubMed] [Google Scholar]
  355. Rumack Barry H. Acetaminophen Overdose. Archives of Internal Medicine. 1981;141(3):380. doi: 10.1001/archinte.1981.00340030112020. [DOI] [PubMed] [Google Scholar]
  356. Saitoh M, Nishitoh H, Fujii M, Takeda K, Tobiume K, Sawada Y, Kawabata M, Miyazono K, Ichijo H. Mammalian thioredoxin is a direct inhibitor of apoptosis signal-regulating kinase (ASK) 1. EMBO J. 1998;17(9):2596–2606. doi: 10.1093/emboj/17.9.2596. [DOI] [PMC free article] [PubMed] [Google Scholar]
  357. Salgia AD, Kosnik SD. When acetaminophen use becomes toxic. Treating acute accidental and intentional overdose. Postgrad Med. 1999;105(4):81–84, 87, 90. doi: 10.3810/pgm.1999.04.673. [DOI] [PubMed] [Google Scholar]
  358. Samiec PS, Drews-Botsch C, Flagg EW, Kurtz JC, Sternberg P, Reed RL, Jones DP. Glutathione in human plasma: decline in association with aging, age-related macular degeneration, and diabetes. Free Radic Biol Med. 1998;24(5):699–704. doi: 10.1016/S0891-5849(97)00286-4. [DOI] [PubMed] [Google Scholar]
  359. Sandalova T, Zhong L, Lindqvist Y, Holmgren A, Schneider G. Three-dimensional structure of a mammalian thioredoxin reductase: implications for mechanism and evolution of a selenocysteine-dependent enzyme. Proc Natl Acad Sci U S A. 2001;98(17):9533–9538. doi: 10.1073/pnas.171178698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  360. Sandberg K, Fellman V, Stigson L, Thiringer K, Hjalmarson O. N-acetylcysteine administration during the first week of life does not improve lung function in extremely low birth weight infants. Biol Neonate. 2004;86(4):275–279. doi: 10.1159/000080089. [DOI] [PubMed] [Google Scholar]
  361. Sandhu C, Belli AM, Oliveira DB. The role of N-acetylcysteine in the prevention of contrast-induced nephrotoxicity. Cardiovasc Intervent Radiol. 2006;29(3):344–347. doi: 10.1007/s00270-005-0127-8. [DOI] [PubMed] [Google Scholar]
  362. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M, Woodbury P, Growdon J, Cotman CW, Pfeiffer E, Schneider LS, Thal LJ. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. N Engl J Med. 1997;336(17):1216–1222. doi: 10.1056/NEJM199704243361704. [DOI] [PubMed] [Google Scholar]
  363. Sasazuki S, Kodama H, Yoshimasu K, Liu Y, Washio M, Tanaka K, Tokunaga S, Kono S, Arai H, Doi Y, Kawano T, Nakagaki O, Takada K, Koyanagi S, Hiyamuta K, Nii T, Shirai K, Ideishi M, Arakawa K, Mohri M, Takeshita A. Relation between green tea consumption and the severity of coronary atherosclerosis among Japanese men and women. Ann Epidemiol. 2000;10(6):401–408. doi: 10.1016/S1047-2797(00)00066-1. [DOI] [PubMed] [Google Scholar]
  364. Sastre J, Pallardo FV, Garcia de la Asuncion J, Vina J. Mitochondria, oxidative stress and aging. Free Radic Res. 2000;32(3):189–198. doi: 10.1080/10715760000300201. [DOI] [PubMed] [Google Scholar]
  365. Sastre J, Pallardo FV, Vina J. Glutathione, oxidative stress and aging. Age. 1996;19(4):129–139. doi: 10.1007/BF02434082. [DOI] [Google Scholar]
  366. Saugstad OD. Bronchopulmonary dysplasia and oxidative stress: are we closer to an understanding of the pathogenesis of BPD? Acta Paediatr. 1997;86(12):1277–1282. doi: 10.1111/j.1651-2227.1997.tb14897.x. [DOI] [PubMed] [Google Scholar]
  367. Saxena S, Kumar D, Srivastava P, Khanna VK, Seth PK. Low levels of platelet glutathione in Eales’ disease. Med Sci Res. 1999;27(9):625–626. [Google Scholar]
  368. Schmidinger M, Budinsky AC, Wenzel C, Piribauer M, Brix R, Kautzky M, Oder W, Locker GJ, Zielinski CC, Steger GG. Glutathione in the prevention of cisplatin induced toxicities. A prospectively randomized pilot trial in patients with head and neck cancer and non small cell lung cancer. Wien Klin Wochenschr. 2000;112(14):617–623. [PubMed] [Google Scholar]
  369. Schmidt AM, Hori O, Chen JX, Li JF, Crandall J, Zhang J, Cao R, Yan SD, Brett J, Stern D. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J Clin Invest. 1995;96(3):1395–1403. doi: 10.1172/JCI118175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  370. Schmidt LE, Knudsen TT, Dalhoff K, Bendtsen F. Effect of acetylcysteine on prothrombin index in paracetamol poisoning without hepatocellular injury. Lancet. 2002;360(9340):1151–1152. doi: 10.1016/S0140-6736(02)11194-9. [DOI] [PubMed] [Google Scholar]
  371. Schnackenberg LK, Chen M, Sun J, Holland RD, Dragan Y, Tong W, Welsh W, Beger RD. Evaluations of the trans-sulfuration pathway in multiple liver toxicity studies. Toxicol Appl Pharmacol. 2009;235(1):25–32. doi: 10.1016/j.taap.2008.11.015. [DOI] [PubMed] [Google Scholar]
  372. Scholze A, Rinder C, Beige J, Riezler R, Zidek W, Tepel M. Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. Circulation. 2004;109(3):369–374. doi: 10.1161/01.CIR.0000109492.65802.AD. [DOI] [PubMed] [Google Scholar]
  373. Schulz JB, Lindenau J, Seyfried J, Dichgans J. Glutathione, oxidative stress and neurodegeneration. Eur J Biochem. 2000;267(16):4904–4911. doi: 10.1046/j.1432-1327.2000.01595.x. [DOI] [PubMed] [Google Scholar]
  374. Seema, Kumar Ramesh, Mandal R. N., Tandon Anita, Randhawa V. S., Mehta G., Batra S., Ray G. N., Kapoor A. K. Serum TNF-alpha and free radical scavengers in neonatal septicemia. The Indian Journal of Pediatrics. 1999;66(4):511–516. doi: 10.1007/BF02727159. [DOI] [PubMed] [Google Scholar]
  375. Sellers EM, Freedman F. Treatment of acetaminophen poisoning. Can Med Assoc J. 1981;125(8):827–829. [PMC free article] [PubMed] [Google Scholar]
  376. Selwa LM. N-acetylcysteine therapy for Unverricht-Lundborg disease. Neurology. 1999;52(2):426–427. doi: 10.1212/WNL.52.2.426. [DOI] [PubMed] [Google Scholar]
  377. Sha SH, Schacht J. Antioxidants attenuate gentamicin-induced free radical formation in vitro and ototoxicity in vivo: D-methionine is a potential protectant. Hear Res. 2000;142(1–2):34–40. doi: 10.1016/S0378-5955(00)00003-4. [DOI] [PubMed] [Google Scholar]
  378. Shan X, Aw TY, Jones DP. Glutathione-dependent protection against oxidative injury. Pharmacol Ther. 1990;47:61–71. doi: 10.1016/0163-7258(90)90045-4. [DOI] [PubMed] [Google Scholar]
  379. Shapiro BL, Smith QT, Warick WJ. Serum glutathione reductase and cystic fibrosis. Pediatr Res. 1975;9(12):885–888. doi: 10.1203/00006450-197512000-00003. [DOI] [PubMed] [Google Scholar]
  380. Shapiro BL, Smith QT, Warwick WJ. Red cell glutathione and glutathione reductase in cystic fibrosis. Proc Soc Exp Biol Med. 1973;144(1):181–183. doi: 10.3181/00379727-144-37552. [DOI] [PubMed] [Google Scholar]
  381. Shenton D, Perrone G, Quinn KA, Dawes IW, Grant CM. Regulation of protein S-thiolation by glutaredoxin 5 in the yeast Saccharomyces cerevisiae. J Biol Chem. 2002;277(19):16853–16859. doi: 10.1074/jbc.M200559200. [DOI] [PubMed] [Google Scholar]
  382. Shriner K, Goetz MB. Severe hepatotoxicity in a patient receiving both acetaminophen and zidovudine. Am J Med. 1992;93(1):94–96. doi: 10.1016/0002-9343(92)90687-7. [DOI] [PubMed] [Google Scholar]
  383. Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol. 2002;40(8):1383–1388. doi: 10.1016/S0735-1097(02)02308-2. [DOI] [PubMed] [Google Scholar]
  384. Sido B, Hack V, Hochlehnert A, Lipps H, Herfarth C, Droge W. Impairment of intestinal glutathione synthesis in patients with inflammatory bowel disease. Gut. 1998;42(4):485–492. doi: 10.1136/gut.42.4.485. [DOI] [PMC free article] [PubMed] [Google Scholar]
  385. Skurnick JH, Bogden JD, Baker H, Kemp FW, Sheffet A, Quattrone G, Louria DB. Micronutrient profiles in HIV-1-infected heterosexual adults. J Acquir Immune Defic Syndr. 1996;12(1):75–83. doi: 10.1097/00042560-199605010-00011. [DOI] [PubMed] [Google Scholar]
  386. Slattery JT, McRorie TI, Reynolds R, Kalhorn TF, Kharasch ED, Eddy AC. Lack of effect of cimetidine on acetaminophen disposition in humans. Clin Pharmacol Ther. 1989;46(5):591–597. doi: 10.1038/clpt.1989.190. [DOI] [PubMed] [Google Scholar]
  387. Slattery JT, Wilson JM, Kalhorn TF, Nelson SD. Dose-dependent pharmacokinetics of acetaminophen: evidence of glutathione depletion in humans. Clin Pharmacol Ther. 1987;41:413–418. doi: 10.1038/clpt.1987.50. [DOI] [PubMed] [Google Scholar]
  388. Smilkstein MJ, Bronstein AC, Linden C, Augenstein WL, Kulig KW, Rumack BH. Acetaminophen overdose: a 48-hour intravenous N-acetylcysteine treatment protocol. Ann Emerg Med. 1991;20(10):1058–1063. doi: 10.1016/S0196-0644(05)81352-6. [DOI] [PubMed] [Google Scholar]
  389. Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of the national multicenter study (1976 to 1985) N Engl J Med. 1988;319(24):1557–1562. doi: 10.1056/NEJM198812153192401. [DOI] [PubMed] [Google Scholar]
  390. Smith CV, Hansen TN, Martin NE, McMicken HW, Elliott SJ. Oxidant stress responses in premature infants during exposure to hyperoxia. Pediatr Res. 1993;34(3):360–365. doi: 10.1203/00006450-199309000-00024. [DOI] [PubMed] [Google Scholar]
  391. Smith CV, Rogers LK, Rabin RL, Maldonado YA, Herzenberg LA, Herzenberg LA, Petru A. Effects of human immunodeficiency virus (HIV) infection on plasma glutathione status in children. Pediatr Res. 1994;35:196A. doi: 10.1203/00006450-199402000-00014. [DOI] [Google Scholar]
  392. Sochman J. N-acetylcysteine in acute cardiology: 10 years later: what do we know and what would we like to know? J Am Coll Cardiol. 2002;39(9):1422–1428. doi: 10.1016/S0735-1097(02)01797-7. [DOI] [PubMed] [Google Scholar]
  393. Song JJ, Rhee JG, Suntharalingam M, Walsh SA, Spitz DR, Lee YJ. Role of glutaredoxin in metabolic oxidative stress. Glutaredoxin as a sensor of oxidative stress mediated by H2O2. J Biol Chem. 2002;277(48):46566–46575. doi: 10.1074/jbc.M206826200. [DOI] [PubMed] [Google Scholar]
  394. Spada C, Treitinger A, Reis M, Masokawa IY, Verdi JC, Luiz MC, Silveira MV, Michelon CM, Avila-Junior S, Gil DO, Ostrowskyl S. The effect of N-acetylcysteine supplementation upon viral load, CD4, CD8, total lymphocyte count and hematocrit in individuals undergoing antiretroviral treatment. Clin Chem Lab Med. 2002;40(5):452–455. doi: 10.1515/CCLM.2002.077. [DOI] [PubMed] [Google Scholar]
  395. Spapen H, Zhang H, Demanet C, Vleminckx W, Vincent JL, Huyghens L. Does N-acetyl-L-cysteine influence cytokine response during early human septic shock? Chest. 1998;113(6):1616–1624. doi: 10.1378/chest.113.6.1616. [DOI] [PubMed] [Google Scholar]
  396. Spies C, Giese C, Meier-Hellmann A, Specht M, Hannemann L, Schaffartzik W, Reinhart K. The effect of prophylactically administered n-acetylcysteine on clinical indicators for tissue oxygenation during hyperoxic ventilation in cardiac risk patients. Anaesthesist. 1996;45(4):343–350. doi: 10.1007/s001010050270. [DOI] [PubMed] [Google Scholar]
  397. Spies CD, Reinhart K, Witt I, Meier-Hellmann A, Hannemann L, Bredle DL, Schaffartzik W. Influence of N-acetylcysteine on indirect indicators of tissue oxygenation in septic shock patients: results from a prospective, randomized, double-blind study. Crit Care Med. 1994;22(11):1738–1746. doi: 10.1097/00003246-199422110-00007. [DOI] [PubMed] [Google Scholar]
  398. Sprietsma JE. Modern diets and diseases: NO-zinc balance. Under Th1, zinc and nitrogen monoxide (NO) collectively protect against viruses, AIDS, autoimmunity, diabetes, allergies, asthma, infectious diseases, atherosclerosis and cancer. Med Hypotheses. 1999;53(1):6–16. doi: 10.1054/mehy.1999.0867. [DOI] [PubMed] [Google Scholar]
  399. Sprince H. Protective action of sulfur compounds against aldehyde toxicants of cigarette smoke. Eur J Respir Dis Suppl. 1985;139:102–112. [PubMed] [Google Scholar]
  400. Sprince H, Parker CM, Smith GG, Gonzales LJ. Protective action of ascorbic acid and sulfur compounds against acetaldehyde toxicity: implications in alcoholism and smoking. Agents Actions. 1975;5(2):164–173. doi: 10.1007/BF02027359. [DOI] [PubMed] [Google Scholar]
  401. Staal FJ, Ela SW, Roederer M, Anderson MT, Herzenberg LA. Glutathione deficiency and human immunodeficiency virus infection. Lancet. 1992;339(8798):909–912. doi: 10.1016/0140-6736(92)90939-Z. [DOI] [PubMed] [Google Scholar]
  402. Staal FJ, Roederer M, Herzenberg LA. Intracellular thiols regulate activation of nuclear factor kappa B and transcription of human immunodeficiency virus. Proc Natl Acad Sci U S A. 1990;87(24):9943–9947. doi: 10.1073/pnas.87.24.9943. [DOI] [PMC free article] [PubMed] [Google Scholar]
  403. Staal FJ, Roederer M, Israelski DM, Bubp J, Mole LA, McShane D, Deresinski SC, Ross W, Sussman H, Raju PA, et al. Intracellular glutathione levels in T cell subsets decrease in HIV-infected individuals. AIDS Res Hum Retrovir. 1992;8(2):305–311. doi: 10.1089/aid.1992.8.305. [DOI] [PubMed] [Google Scholar]
  404. Stafanger G, Garne S, Howitz P, Morkassel E, Koch C. The clinical effect and the effect on the ciliary motility of oral N-acetylcysteine in patients with cystic fibrosis and primary ciliary dyskinesia. Eur Respir J. 1988;1(2):161–167. [PubMed] [Google Scholar]
  405. Stafanger G, Koch C. N-acetylcysteine in cystic fibrosis and Pseudomonas aeruginosa infection: clinical score, spirometry and ciliary motility. Eur Respir J. 1989;2(3):234–237. [PubMed] [Google Scholar]
  406. Stewart DM, Dillman RO, Kim HS, Stewart K. Acetaminophen overdose: a growing health care hazard. Clin Toxicol. 1979;14(5):507–513. doi: 10.3109/15563657908992462. [DOI] [PubMed] [Google Scholar]
  407. Stey C, Steurer J, Bachmann S, Medici TC, Tramer MR. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review [In Process Citation] Eur Respir J. 2000;16(2):253–262. doi: 10.1034/j.1399-3003.2000.16b12.x. [DOI] [PubMed] [Google Scholar]
  408. Stiksa G, Nemcek K, Melin S. Effects of inhaled N-acetylcysteine in combination with terbutaline. Eur J Respir Dis. 1984;65(4):278–282. [PubMed] [Google Scholar]
  409. Straface E, Rivabene R, Masella R, Santulli M, Paganelli R, Malorni W. Structural changes of the erythrocyte as a marker of non-insulin-dependent diabetes: protective effects of N-acetylcysteine. Biochem Biophys Res Commun. 2002;290(5):1393–1398. doi: 10.1006/bbrc.2002.6340. [DOI] [PubMed] [Google Scholar]
  410. Suarez M, Beloqui O, Ferrer JV, Gil B, Qian C, Garcia N, Civeira P, Prieto J. Glutathione depletion in chronic hepatitis C. Int Hepatol Commun. 1993;1:215–221. doi: 10.1016/0928-4346(93)90043-F. [DOI] [Google Scholar]
  411. Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283(1):74–80. doi: 10.1001/jama.283.1.74. [DOI] [PubMed] [Google Scholar]
  412. Sung L, Simons JA, Dayneka NL. Dilution of intravenous N-acetylcysteine as a cause of hyponatremia. Pediatrics. 1997;100(3 Pt 1):389–391. doi: 10.1542/peds.100.3.389. [DOI] [PubMed] [Google Scholar]
  413. Suter PM, Domenighetti G, Schaller M-D, Laverriere M-C, Ritz R, Perret C. N-acetylcysteine enhances recovery from acute lung injury in man. A randomized, double-blind, placebo-controlled clinical study. Chest. 1994;105:190–194. doi: 10.1378/chest.105.1.190. [DOI] [PubMed] [Google Scholar]
  414. Svendsen JH, Klarlund K, Aldershvile J, Waldorff S. N-acetylcysteine modifies the acute effects of isosorbide-5-mononitrate in angina pectoris patients evaluated by exercise testing. J Cardiovasc Pharmacol. 1989;13(2):320–323. doi: 10.1097/00005344-198902000-00022. [DOI] [PubMed] [Google Scholar]
  415. Szakmany T, Marton S, Molnar Z. Lack of effect of prophylactic N-acetylcysteine on postoperative organ dysfunction following major abdominal tumour surgery: a randomized, placebo-controlled, double-blinded clinical trial. Anaesth Intensive Care. 2003;31(3):267–271. doi: 10.1177/0310057X0303100304. [DOI] [PubMed] [Google Scholar]
  416. Taniguchi N, Higashi T, Sakamoto Y, Meister A, editors. Glutathione centennial: molecular perspectives and clinical applications. New York: Academic Press; 1989. [Google Scholar]
  417. Tatebe S, Sinicrope FA, Kuo MT. Induction of multidrug resistance proteins MRP1 and MRP3 and gamma-glutamylcysteine synthetase gene expression by nonsteroidal anti-inflammatory drugs in human colon cancer cells. Biochem Biophys Res Commun. 2002;290(5):1427–1433. doi: 10.1006/bbrc.2002.6367. [DOI] [PubMed] [Google Scholar]
  418. Tenenbein M. Hypersensitivity-like reactions to N-acetylcysteine. Vet Hum Toxicol. 1984;26(Suppl 2):3–5. [PubMed] [Google Scholar]
  419. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med. 2000;343:180–184. doi: 10.1056/NEJM200007203430304. [DOI] [PubMed] [Google Scholar]
  420. Tepel M, van der Giet M, Statz M, Jankowski J, Zidek W. The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure. A randomized, controlled trial. Circulation. 2003;107:992. doi: 10.1161/01.CIR.0000050628.11305.30. [DOI] [PubMed] [Google Scholar]
  421. Tepel M, Zidek W. Acetylcysteine for radiocontrast nephropathy. Curr Opin Crit Care. 2001;7(6):390–392. doi: 10.1097/00075198-200112000-00004. [DOI] [PubMed] [Google Scholar]
  422. Tessier D, Khalil A, Fulop T. Effects of an oral glucose challenge on free radicals/antioxidants balance in an older population with type II diabetes. J Gerontol A Biol Sci Med Sci. 1999;54(11):M541–M545. doi: 10.1093/gerona/54.11.M541. [DOI] [PubMed] [Google Scholar]
  423. Tice JA, Ross E, Coxson PG, Rosenberg I, Weinstein MC, Hunink MG, Goldman PA, Williams L, Goldman L. Cost-effectiveness of vitamin therapy to lower plasma homocysteine levels for the prevention of coronary heart disease: effect of grain fortification and beyond. JAMA. 2001;286(8):936–943. doi: 10.1001/jama.286.8.936. [DOI] [PubMed] [Google Scholar]
  424. Todisco T, Polidori R, Rossi F, Iannacci L, Bruni B, Fedeli L, Palumbo R. Effect of N-acetylcysteine in subjects with slow pulmonary mucociliary clearance. Eur J Respir Dis Suppl. 1985;139:136–141. [PubMed] [Google Scholar]
  425. Tossios P, Bloch W, Huebner A, Raji MR, Dodos F, Klass O, Suedkamp M, Kasper SM, Hellmich M, Mehlhorn U. N-acetylcysteine prevents reactive oxygen species-mediated myocardial stress in patients undergoing cardiac surgery: results of a randomized, double-blind, placebo-controlled clinical trial. J Thorac Cardiovasc Surg. 2003;126(5):1513–1520. doi: 10.1016/S0022-5223(03)00968-1. [DOI] [PubMed] [Google Scholar]
  426. Travaline JM, Sudarshan S, Roy BG, Cordova F, Leyenson V, Criner GJ. Effect of N-acetylcysteine on human diaphragm strength and fatigability. Am J Respir Crit Care Med. 1997;156(5):1567–1571. doi: 10.1164/ajrccm.156.5.96-09133. [DOI] [PubMed] [Google Scholar]
  427. Treeprasertsuk S, Krudsood S, Tosukhowong T, Maek ANW, Vannaphan S, Saengnetswang T, Looareesuwan S, Kuhn WF, Brittenham G, Carroll J. N-acetylcysteine in severe falciparum malaria in Thailand. Southeast Asian J Trop Med Public Health. 2003;34(1):37–42. [PMC free article] [PubMed] [Google Scholar]
  428. Tripi S, Di Gaetano G, Soresi M, Carroccio A, Bonfissuto G, Savi A, Vuturo O, Montalto G. Acetylcysteine therapy for chronic hepatitis C: are its effects synergistic with interferon alpha? A pilot study. Clin Drug Invest. 1998;16(4):297–302. doi: 10.2165/00044011-199816040-00004. [DOI] [PubMed] [Google Scholar]
  429. Uden S, Bilton D, Guyan PM, Kay PM, Braganza JM. Rationale for antioxidant therapy in pancreatitis and cystic fibrosis. Adv Exp Med Biol. 1990;264:555–572. doi: 10.1007/978-1-4684-5730-8_84. [DOI] [PubMed] [Google Scholar]
  430. Unverferth DV, Jagadeesh JM, Unverferth BJ, Magorien RD, Leier CV, Balcerzak SP. Attempt to prevent doxorubicin-induced acute human myocardial morphologic damage with acetylcysteine. J Natl Cancer Inst. 1983;71(5):917–920. [PubMed] [Google Scholar]
  431. Upritchard JE, Sutherland WH, Mann JI. Effect of supplementation with tomato juice, vitamin E, and vitamin C on LDL oxidation and products of inflammatory activity in type 2 diabetes. Diabetes Care. 2000;23(6):733–738. doi: 10.2337/diacare.23.6.733. [DOI] [PubMed] [Google Scholar]
  432. Usal A, Acarturk E, Yuregir GT, Unlukurt I, Demirci C, Kurt HI, Birand A. Decreased glutathione levels in acute myocardial infarction. Jpn Heart J. 1996;37(2):177–182. doi: 10.1536/ihj.37.177. [DOI] [PubMed] [Google Scholar]
  433. van Bakel MM, Printzen G, Wermuth B, Wiesmann UN. Antioxidant and thyroid hormone status in selenium-deficient phenylketonuric and hyperphenylalaninemic patients. Am J Clin Nutr. 2000;72(4):976–981. doi: 10.1093/ajcn/72.4.976. [DOI] [PubMed] [Google Scholar]
  434. van Dalen EC, Caron HN, Dickinson HO, Kremer LC. Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. 2005;1:CD003917. doi: 10.1002/14651858.CD003917.pub2. [DOI] [PubMed] [Google Scholar]
  435. Van Schooten FJ, Nia AB, De Flora S, D’Agostini F, Izzotti A, Camoirano A, Balm AJ, Dallinga JW, Bast A, Haenen GR, Van’t Veer L, Baas P, Sakai H, Van Zandwijk N. Effects of oral administration of N-acetyl-L-cysteine: a multi-biomarker study in smokers. Cancer Epidemiol Biomark Prev. 2002;11(2):167–175. [PubMed] [Google Scholar]
  436. Vecchiarelli A, Dottorini M, Pietrella D, Cociani C, Eslami A, Todisco T, Bistoni F. Macrophage activation by N-acetyl-cysteine in COPD patients. Chest. 1994;105(3):806–811. doi: 10.1378/chest.105.3.806. [DOI] [PubMed] [Google Scholar]
  437. Verhagen H, Hageman GJ, Rauma AL, Versluis-de Haan G, van Herwijnen MH, de Groot J, Torronen R, Mykkanen H. Biomonitoring the intake of garlic via urinary excretion of allyl mercapturic acid. Br J Nutr. 2001;86(Suppl 1):S111–S114. doi: 10.1079/BJN2001343. [DOI] [PubMed] [Google Scholar]
  438. Verhulst M-L, Van Oijen AHAM, Roelofs HMJ, Peters WHM, Jansen JBMJ. Antral glutathione concentration and glutathione S-transferase activity in patients with and without Helicobacter pylori. Dig Dis Sci. 2000;45(3):629–632. doi: 10.1023/A:1005426130826. [DOI] [PubMed] [Google Scholar]
  439. Verjee ZH, Behal R. Protein-calorie malnutrition: a study of red blood cell and serum enzymes during and after crisis. Clin Chim Acta. 1976;70(1):139–147. doi: 10.1016/0009-8981(76)90016-4. [DOI] [PubMed] [Google Scholar]
  440. Verstraeten JM. Mucolytic treatment in chronic obstructive pulmonary disease. Double-blind comparative clinical trial with N-acetylcysteine, bromhexine and placebo. Acta Tuberc Pneumol Belg. 1979;70(1):71–80. [PubMed] [Google Scholar]
  441. Villa P, Saccani A, Sica A, Ghezzi P. Glutathione protects mice from lethal sepsis by limiting inflammation and potentiating host defense. J Infect Dis. 2002;185(8):1115–1120. doi: 10.1086/340042. [DOI] [PubMed] [Google Scholar]
  442. Vita JA, Frei B, Holbrook M, Gokce N, Leaf C, Keaney Jr JF. L-2-oxothiazolidine-4-carboxylic acid reverses endothelial dysfunction in patients with coronary artery disease. J Clin Invest. 1998;101(6):1408–1414. doi: 10.1172/JCI1155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  443. Vlamis-Gardikas A, Holmgren A. Thioredoxin and glutaredoxin isoforms. Methods Enzymol. 2002;347:286–296. doi: 10.1016/S0076-6879(02)47028-0. [DOI] [PubMed] [Google Scholar]
  444. Volkin DB, Klibanov AM. Thermal destruction processes in proteins involving cystine residues. J Biol Chem. 1987;262(7):2945–2950. [PubMed] [Google Scholar]
  445. Wagdi P, Fluri M, Aeschbacher B, Fikrle A, Meier B. Cardioprotection in patients undergoing chemo- and/or radiotherapy for neoplastic disease. A pilot study. Jpn Heart J. 1996;37(3):353–359. doi: 10.1536/ihj.37.353. [DOI] [PubMed] [Google Scholar]
  446. Wagdi P, Rouvinez G, Fluri M, Aeschbacher B, Thoni A, Schefer H, Meier B. Cardioprotection in chemo- and radiotherapy for malignant diseases – an echocardiographic pilot study. Schweiz Rundsch Med Prax. 1995;84(43):1220–1223. [PubMed] [Google Scholar]
  447. Walmsley SL, Winn LM, Harrison ML, Uetrecht JP, Wells PG. Oxidative stress and thiol depletion in plasma and peripheral blood lymphocytes from HIV-infected patients: toxicological and pathological implications. AIDS. 1997;11(14):1689–1697. doi: 10.1097/00002030-199714000-00005. [DOI] [PubMed] [Google Scholar]
  448. Walters MT, Rubin CE, Keightley SJ, Ward CD, Cawley MI. A double-blind, cross-over, study of oral N-acetylcysteine in Sjogren’s syndrome. Scand J Rheumatol Suppl. 1986;61:253–258. [PubMed] [Google Scholar]
  449. Wang J, Boja ES, Tan W, Tekle E, Fales HM, English S, Mieyal JJ, Chock PB. Reversible Glutathionylation Regulates Actin Polymerization in A431 Cells. J Biol Chem. 2001;276(51):47763–47766. doi: 10.1074/jbc.C100415200. [DOI] [PubMed] [Google Scholar]
  450. Ward KP, Arthur JR, Russell G, Aggett PJ. Blood selenium content and glutathione peroxidase activity in children with cystic fibrosis, coeliac disease, asthma, and epilepsy. Eur J Pediatr. 1984;142(1):21–24. doi: 10.1007/BF00442584. [DOI] [PubMed] [Google Scholar]
  451. Watt G, Jongsakul K, Ruangvirayuth R. A pilot study of N-acetylcysteine as adjunctive therapy for severe malaria. QJM. 2002;95(5):285–290. doi: 10.1093/qjmed/95.5.285. [DOI] [PubMed] [Google Scholar]
  452. Weber S, Auclert L, Touiza K, Pellois A, Guerin C, Blin P, Guerin F. Evaluation of tolerance during intravenous administration of low dose of isosorbide dinitrate in the treatment of unstable angina. Arch Mal Coeur Vaiss. 1992;85(1):59–65. [PubMed] [Google Scholar]
  453. Weigand MA, Plachky J, Thies JC, Spies-Martin D, Otto G, Martin E, Bardenheuer HJ. N-acetylcysteine attenuates the increase in alpha-glutathione S-transferase and circulating ICAM-1 and VCAM-1 after reperfusion in humans undergoing liver transplantation. Transplantation. 2001;72(4):694–698. doi: 10.1097/00007890-200108270-00023. [DOI] [PubMed] [Google Scholar]
  454. Weikert LF, Bernard GR. Pharmacotherapy of sepsis. Clin Chest Med. 1996;17(2):289–305. doi: 10.1016/S0272-5231(05)70315-4. [DOI] [PubMed] [Google Scholar]
  455. White AC, Thannickal VJ, Fanburg BL. Glutathione deficiency in human disease. J Nutr Biochem. 1994;5:218–226. doi: 10.1016/0955-2863(94)90039-6. [DOI] [Google Scholar]
  456. Whitekus MJ, Li N, Zhang M, Wang M, Horwitz MA, Nelson SK, Horwitz LD, Brechun N, Diaz-Sanchez D, Nel AE. Thiol antioxidants inhibit the adjuvant effects of aerosolized diesel exhaust particles in a murine model for ovalbumin sensitization. J Immunol. 2002;168(5):2560–2567. doi: 10.4049/jimmunol.168.5.2560. [DOI] [PubMed] [Google Scholar]
  457. Wiklund O, Fager G, Andersson A, Lundstam U, Masson P, Hultberg B. N-acetylcysteine treatment lowers plasma homocysteine but not serum lipoprotein(a) levels. Atherosclerosis. 1996;119(1):99–106. doi: 10.1016/0021-9150(95)05635-1. [DOI] [PubMed] [Google Scholar]
  458. Winkler E, Halkin H. Paracetamol overdose in Israel–1992. Isr J Med Sci. 1992;28(11):811–812. [PubMed] [Google Scholar]
  459. Winklhofer-Roob BM. Cystic fibrosis: nutritional status and micronutrients [In Process Citation] Curr Opin Clin Nutr Metab Care. 2000;3(4):293–297. doi: 10.1097/00075197-200007000-00009. [DOI] [PubMed] [Google Scholar]
  460. Winterbourn CC, Peskin AV, Parsons-Mair HN. Thiol oxidase activity of copper, zinc superoxide dismutase. J Biol Chem. 2002;277(3):1906–1911. doi: 10.1074/jbc.M107256200. [DOI] [PubMed] [Google Scholar]
  461. Woo OF, Mueller PD, Olson KR, Anderson IB, Kim SY. Shorter duration of oral N-acetylcysteine therapy for acute acetaminophen overdose. Ann Emerg Med. 2000;35(4):363–368. doi: 10.1016/S0196-0644(00)70055-2. [DOI] [PubMed] [Google Scholar]
  462. Xu D, Finkel T. A role for mitochondria as potential regulators of cellular life span. Biochem Biophys Res Commun. 2002;294(2):245–248. doi: 10.1016/S0006-291X(02)00464-3. [DOI] [PubMed] [Google Scholar]
  463. Yalcin E, Altin F, Cinhuseyinoglue F, Arslan MO. N-acetylcysteine in chronic blepharitis. Cornea. 2002;21(2):164–168. doi: 10.1097/00003226-200203000-00007. [DOI] [PubMed] [Google Scholar]
  464. Yang ES, Richter C, Chun JS, Huh TL, Kang SS, Park JW. Inactivation of NADP(+)-dependent isocitrate dehydrogenase by nitric oxide. Free Radic Biol Med. 2002;33(7):927–937. doi: 10.1016/S0891-5849(02)00981-4. [DOI] [PubMed] [Google Scholar]
  465. Yiengpruksawan A, Lightdale CJ, Gerdes H, Botet JF. Mucolytic-antifoam solution for reduction of artifacts during endoscopic ultrasonography: a randomized controlled trial. Gastrointest Endosc. 1991;37(5):543–546. doi: 10.1016/S0016-5107(91)70825-0. [DOI] [PubMed] [Google Scholar]
  466. Yoshida K, Hirokawa J, Tagami S, Kawakami Y, Urata Y, Kondo T. Weakened cellular scavenging activity against oxidative stress in diabetes mellitus: regulation of glutathione synthesis and efflux. Diabetologia. 1995;38(2):201–210. doi: 10.1007/BF00400095. [DOI] [PubMed] [Google Scholar]
  467. Yucel D, Aydogdu S, Cehreli S, Saydam G, Canatan H, Senes M, Topkaya BC, Nebioglu S. Increased oxidative stress in dilated cardiomyopathic heart failure. Clin Chem. 1998;44(1):148–154. [PubMed] [Google Scholar]
  468. Zhong L, Arner ES, Holmgren A. Structure and mechanism of mammalian thioredoxin reductase: the active site is a redox-active selenolthiol/selenenylsulfide formed from the conserved cysteine-selenocysteine sequence. Proc Natl Acad Sci U S A. 2000;97(11):5854–5859. doi: 10.1073/pnas.100114897. [DOI] [PMC free article] [PubMed] [Google Scholar]
  469. Zhong L, Holmgren A. Essential role of selenium in the catalytic activities of mammalian thioredoxin reductase revealed by characterization of recombinant enzymes with selenocysteine mutations. J Biol Chem. 2000;275(24):18121–18128. doi: 10.1074/jbc.M000690200. [DOI] [PubMed] [Google Scholar]
  470. Zhong L, Persson K, Sandalova T, Schneider G, Holmgren A. Purification, crystallization and preliminary crystallographic data for rat cytosolic selenocysteine 498 to cysteine mutant thioredoxin reductase. Acta Crystallogr D Biol Crystallogr. 2000;56(Pt 9):1191–1193. doi: 10.1107/S0907444900009458. [DOI] [PubMed] [Google Scholar]
  471. Zimmerman RJ, Marafino BJ, Jr, Chan A, Landre P, Winkelhake JL. The role of oxidant injury in tumor cell sensitivity to recombinant human tumor necrosis factor in vivo. Implications for mechanism of action. J Immunol. 1989;142:1405–1409. [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Online Table 20.1 (15.7KB, docx)

Studies excluded from this review (DOCX 31 kb)

Online Table 20.2 (40.5KB, docx)

NAC treatment in randomized placebo-controlled studies (DOCX 60 kb)

Online Table 20.3 (27.4KB, docx)

Intravenous (IV) NAC (DOCX 44 kb)

Online Table 20.4 (42.6KB, docx)

Observational NAC treatment studies (DOCX 40 kb)

Articles from The Therapeutic Use of N-Acetylcysteine (NAC) in Medicine are provided here courtesy of Nature Publishing Group

RESOURCES